<SEC-DOCUMENT>0001104659-24-065715.txt : 20240529
<SEC-HEADER>0001104659-24-065715.hdr.sgml : 20240529
<ACCEPTANCE-DATETIME>20240528214416
ACCESSION NUMBER:		0001104659-24-065715
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240529
DATE AS OF CHANGE:		20240528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278890
		FILM NUMBER:		24993845

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>tm2412319d10_424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule&nbsp;424(b)(4)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-278890</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2412319d10_424b4img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Applied DNA Sciences,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 9,230,769 Units, Each Unit Consisting
of One Share of Common Stock or One </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pre-Funded Warrant to Purchase One Share of
Common Stock, One Series A Warrant to Purchase One Share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Placement Agent Warrants to Purchase Up to
461,538 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 28,153,845 Shares of Common Stock Underlying
the Pre-Funded Warrants, Series A Warrants, Series B Warrants and Placement Agent Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering 9,230,769
units (the &ldquo;Units&rdquo;), each Unit consisting of one share of our common stock, $0.001 par value per share, one Series A warrant
(&ldquo;Series A Warrant&rdquo;) to purchase one share of common stock and one Series B warrant (&ldquo;Series B Warrant&rdquo;, and,
with the Series A Warrants, the &ldquo;Series Warrants&rdquo;) to purchase one share of common stock, at the public offering price of
$1.30 per Unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Units have no stand-alone
rights and will not be certificated or issued as stand-alone securities. The exercisability of the Series Warrants will be available
only upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market
(the &ldquo;Warrant Stockholder Approval&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Series A Warrant offered
hereby will become exercisable beginning on the date of the Warrant Stockholder Approval at an exercise price of $1.99 per share of common
stock, and will expire five years from the date of the Warrant Stockholder Approval. Each Series B Warrant offered hereby will become
exercisable beginning on the date of the Warrant Stockholder Approval at an exercise price of $1.99&nbsp;per share of common stock, and
will expire one year from the date of the Warrant Stockholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the alternate cashless
exercise option of the Series&nbsp;B Warrants, the holder of the Series&nbsp;B Warrant, has the right to receive an aggregate number
of shares equal to the product of (x)&nbsp;the aggregate number of shares of common stock that would be issuable upon a cash exercise
of the Series&nbsp;B Warrant and (y)&nbsp;3.0. In addition, the Series&nbsp;A Warrants and Series&nbsp;B Warrants will include a provision
that resets their respective exercise price in the event of a reverse split of our common stock, to a price equal to the lesser of (i)&nbsp;the
then exercise price and (ii)&nbsp;lowest volume weighted average price (VWAP) during the period commencing five trading days immediately
preceding and the five trading days commencing on the date we effect a reverse stock split in the future with a proportionate adjustment
to the number of shares underlying the Series&nbsp;A Warrants and Series&nbsp;B Warrants. Further, subject to certain exceptions, the
Series&nbsp;A Warrants will provide for an adjustment to the exercise price and number of shares underlying the Series&nbsp;A Warrants
upon any issuance by us of our common stock or common stock equivalents at a price per share that is less than the exercise price of
the Series&nbsp;A Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that we are
unable to obtain the Warrant Stockholder Approval, the Series&nbsp;Warrants will not be exercisable and therefore will have no value.
See the Risk Factor on page&nbsp;13 relating to the Series&nbsp;A Warrants and Series&nbsp;B Warrants and Warrant Stockholder Approval,
and see the section entitled &ldquo;Warrant Stockholder Approval&rdquo; on page&nbsp;22&nbsp; for additional details regarding the Warrant
Stockholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also offering to each
purchaser of Units that would otherwise result in the purchaser&rsquo;s beneficial ownership exceeding 4.99% (or, at the election of
the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase
Units consisting of one pre-funded warrant (in lieu of one share of common stock, each a &ldquo;Pre-Funded Warrant&rdquo;), one Series&nbsp;A
Warrant and one Series&nbsp;B Warrant. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise
any portion of its Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at
the election of the holder, such limit may be increased to up to 9.99%) of the number of shares of common stock outstanding immediately
after giving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one share of common stock. The purchase price of
each Unit including a Pre-Funded Warrant will be equal to the price per Unit including one share of common stock, minus $0.0001, and
the remaining exercise price of each Pre-Funded Warrant will equal $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable
(subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
For each Unit including a Pre-Funded Warrant we sell (without regard to any limitation on exercise set forth therein), the number of
Units including a share of common stock we are offering will be decreased on a one-for-one basis. The Pre-Funded Warrant may be exercised
on a cashless basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus also includes
the shares of common stock issuable upon exercise of the Series&nbsp;A Warrants, Series&nbsp;B Warrants, and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common stock and Pre-Funded
Warrants can each be purchased in this offering only with the accompanying Series&nbsp;A Warrants and Series&nbsp;B Warrants that are
part of a Unit, but the components of the Units will be immediately separable and will be issued separately in this offering. See &ldquo;Description
of Securities&rdquo; in this prospectus for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on The Nasdaq Capital Market under the symbol &ldquo;APDN.&rdquo; On May&nbsp;24, 2024, the last reported sale price of our common stock
on The Nasdaq Capital Market was $1.99 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged Craig-Hallum
Capital Group LLC (&ldquo;Craig-Hallum&rdquo;) and Laidlaw&nbsp;&amp; Company (UK) Ltd. (&ldquo;Laidlaw&rdquo;, and each of Craig-Hallum
and Laidlaw, a &ldquo;Placement Agent&rdquo; and collectively, the &ldquo;Co-Placement Agents&rdquo;), to act as our exclusive placement
agents in connection with this offering. The Co-Placement Agents have agreed to use their best efforts to arrange for the sale of the
securities offered by this prospectus. The Co-Placement Agents are not purchasing or selling any of the securities we are offering and
the Co-Placement Agents are not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have
agreed to pay to the Co-Placement Agents the placement agent fees set forth in the table below, which assumes that we sell all of the
securities offered by this prospectus. There is no minimum number of securities or minimum aggregate amount of proceeds that is a condition
of the closing of this offering. We will bear all costs associated with the offering. See &ldquo;Plan of Distribution&rdquo; on page&nbsp;23
of this prospectus for more information regarding these arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no established public
trading market for the Series&nbsp;Warrants or the Pre-Funded Warrants, and we do not expect a market to develop. In addition, we do
not intend to apply for the listing of the Series&nbsp;Warrants or the Pre-Funded Warrants on any national securities exchange. Without
an active trading market, the liquidity of the Series&nbsp;Warrants and the Pre-Funded Warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">This
offering will terminate on June&nbsp;30, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion)
prior to that date. We will have one closing for all the securities purchased in this offering. The public offering price per Unit will
be fixed for the duration of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell fewer than all
securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will
not receive a refund if we do not sell all of the securities offered hereby. We have not established an escrow account in conjunction
with this offering. Because there is no escrow account and no minimum number of securities or amount of proceeds, investors could be
in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended
uses of the proceeds as described in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise indicated,
all share and per share information in this prospectus gives effect to the reverse stock split of the Company&rsquo;s outstanding common
stock at a ratio of one-for-twenty shares, which was approved by our Board of Directors on April&nbsp;21, 2024 and was effected as of
12:01 a.m.&nbsp;Eastern Time on Thursday, April&nbsp;25, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per<BR>
Share and<BR>
Series&nbsp;Warrants</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Pre-Funded<BR>
Warrant and<BR>
Series&nbsp;Warrants</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; width: 61%"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1.30</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1.2999</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">12,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Placement Agent fees<SUP>(1)</SUP>&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">$</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.091</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">$</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.09099</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">$</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">840,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us<SUP>(2)</SUP>&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1.209</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1.20891</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">11,160,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to pay the
    Co-Placement Agents a total cash fee equal to 7.0% of the aggregate gross proceeds raised in this offering and to reimburse the Co-Placement
    Agents for their legal fees and expenses and other out-of-pocket expenses in an amount up to $110,000. In addition, we have agreed
    to issue to the Co-Placement Agents warrants to purchase up to a number of shares of our common stock equal to 5.0% of the number
    of Units being offered in this offering at an exercise price equal to that of the Series&nbsp;Warrants and with an expiration date
    of five years from the commencement of sales. See &ldquo;<I>Plan of Distribution</I>&rdquo; for a description of the compensation
    to be received by the Co-Placement Agents.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify">This does not include proceeds from the cash exercise of the Pre-Funded Warrants, if any, or Series&nbsp;Warrants.
For more information, see &ldquo;<I>Plan of Distribution</I>.&rdquo;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;12 of this prospectus and elsewhere in this prospectus
for a discussion of information that should be considered in connection with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The securities are not being offered in any
jurisdiction where the offer is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delivery of the securities
offered hereby is expected to be made on or about May&nbsp;29, 2024, subject to satisfaction of certain customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Craig-Hallum</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Laidlaw&nbsp;&amp;
    Company (UK) Ltd.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this Prospectus is&nbsp;May&nbsp;28,
2024.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; width: 90%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">About
    this Prospectus</FONT></A></TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: right"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Forward-Looking
    Statements</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Prospectus
    Summary</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Summary
    of the Offering</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Risk
    Factors</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Use
    of Proceeds</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Market
    Price of our Common Stock and Related Stockholder Matters</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Capitalization</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Dilution</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Description
    of Securities</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">PLAN
    OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Experts</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Legal
    Matters</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Where
    you can find more information</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL
    CHANGES</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></A></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Incorporation
    by Reference</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: right"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="a_001"></A><B>ABOUT
THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or incorporated
by reference in this prospectus, or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized
anyone else to provide you with different information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not authorized any
dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus or any related free writing prospectus. You must not rely upon any information or representation not contained or
incorporated by reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus,
if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities
to which they relate, nor do this prospectus and any related free writing prospectus, if any, constitute an offer to sell or the solicitation
of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.
You should not assume that the information contained in this prospectus and any related free writing prospectus, if any, is accurate
on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference
is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any related
free writing prospectus is delivered or securities are sold on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not done anything
that would permit this offering or possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where
action for that purpose is required, other than in the United States. You are required to inform yourself about and to observe any restrictions
relating as to this offering and the distribution of this prospectus and any such free writing prospectus outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We further note that the
representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated
by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the
purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant
to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><FONT STYLE="text-transform: uppercase"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus <FONT STYLE="background-color: white">and
the documents that we incorporate herein by reference</FONT> contain forward-looking statements concerning our business, operations and
financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance
and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such as &ldquo;can&rdquo;, &ldquo;may&rdquo;, &ldquo;could&rdquo;,
 &ldquo;should&rdquo;, &ldquo;assume&rdquo;, &ldquo;forecasts&rdquo;, &ldquo;believe&rdquo;, &ldquo;designed to&rdquo;, &ldquo;will&rdquo;,
 &ldquo;expect&rdquo;, &ldquo;plan&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;estimate&rdquo;, &ldquo;potential&rdquo;, &ldquo;position&rdquo;,
 &ldquo;predicts&rdquo;, &ldquo;strategy&rdquo;, &ldquo;guidance&rdquo;, &ldquo;intend&rdquo;, &ldquo;budget&rdquo;, &ldquo;seek&rdquo;,
 &ldquo;project&rdquo; or &ldquo;continue&rdquo;, or the negative thereof or other comparable terminology regarding beliefs, plans, expectations
or intentions regarding the future. You should read statements that contain these words carefully because they:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discuss our future expectations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contain projections of
    our future results of operations or of our financial condition; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state other &ldquo;forward-looking&rdquo;
    information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe it is important
to communicate our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and
projections about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly,
our actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements
due to a variety of factors and risks, including, but not limited to, those set forth under &ldquo;Risk Factors&rdquo; in this prospectus
and in the documents we incorporate by reference herein, and the following factors and risks:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations of future
    revenues, margins, expenditures, capital or other funding requirements;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the adequacy of our cash
    and working capital to fund present and planned operations and growth; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the substantial doubt relating
    to our ability to continue as a going concern;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need for additional
    financing which may in turn require the issuance of additional shares of common stock, preferred stock, warrants or other debt or
    equity securities (including convertible securities) which would dilute the ownership held by stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our business strategy and
    the timing of our expansion plans, including the development of new production facilities for our Therapeutic DNA Production Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demand for Therapeutic
    DNA Production Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demand for DNA Tagging
    Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demand for MDx Testing
    Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations concerning
    existing or potential development and license agreements for third-party collaborations or joint ventures;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory approval and
    compliance for our Therapeutic DNA Production Services, upon which our business strategy is substantially dependent;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether we are able to
    achieve the benefits expected from the acquisition of Spindle;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of governmental
    regulations generally;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations of when
    regulatory submissions may be filed or when regulatory approvals may be received;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations concerning
    product candidates for our technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations of when
    or if we will become profitable; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 24px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet the
    listing standards of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) to maintain the listing of our common stock on Nasdaq particularly
    in light of the notification by Nasdaq of our failure to comply with minimum stockholder equity requirements;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of the reverse
    stock split on the liquidity of our common stock and our ability to satisfy the investing requirements of new investors, including
    institutional investors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential dilution
    of our existing stockholders due to the effective increase in the number of shares of our common stock available for issuance as
    a result of our reverse stock split; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that our laboratory
    developed tests (&ldquo;LDTs&rdquo;) may become subject to additional regulatory requirements due to FDA rulemaking activity, and
    that compliance with such requirements may be expensive and time-consuming, resulting in significant or unanticipated delays.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any or all of our forward-looking
statements may turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and
uncertainties. Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements.
Among the factors that could affect future results are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inherent uncertainties
    of product development based on our new and as yet not fully proven technologies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risks and uncertainties
    regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments when tested clinically;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">formulations and treatments
    that utilize our Therapeutic DNA Production Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inherent uncertainties
    associated with clinical trials of product candidates, including product candidates that utilize our Therapeutic DNA Production Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inherent uncertainties
    associated with the process of obtaining regulatory clearance or approval to market product candidates, including product candidates
    that utilize our Therapeutic DNA Production Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inherent uncertainties
    associated with the process of obtaining regulatory clearance for our MDx Testing Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inherent uncertainties
    associated with commercialization of products that have received regulatory clearance or approval, including products that utilize
    our Therapeutic DNA Production Services;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic and industry conditions
    generally and in our specific markets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the volatility of, and
    decline in, our stock price; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain the
    necessary financing to fund our operations and effect our strategic development plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All forward-looking statements
and risk factors included in this prospectus are made as of the date hereof, and all forward-looking statements and risk factors included
in documents incorporated herein by reference are made as of their original date, in each case based on information available to us as
of the date hereof, or in the case of documents incorporated by reference, the original date of any such document, and we assume no obligations
to update any forward-looking statement or risk factor, unless we are required to do so by law. If we do update one or more forward-looking
statements, no inference should be drawn that we will make updates with respect to other forward-looking statements or that we will make
any further updates to those forward-looking statements at any future time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
may include our plans and objectives for future operations, including plans and objectives relating to our products and our future economic
performance, projections, business strategy and timing and likelihood of success. Assumptions relating to the foregoing involve judgments
with respect to, among other things, future economic, competitive and market conditions, future business decisions, demand for our products
and services, and the time and money required to successfully complete development and commercialization of our technologies, all of
which are difficult or impossible to predict accurately and many of which are beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the assumptions underlying
the forward-looking statements contained in this prospectus could prove inaccurate and, therefore, we cannot assure you that any of the
results or events contemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent
in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee
by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward looking-statements contained
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary highlights certain
information about us, this offering and information appearing elsewhere in this prospectus and in the documents we incorporate by reference
in this prospectus. This summary is not complete and does not contain all of the information that you should consider before investing
in our securities. After you carefully read this summary, to fully understand our Company and this offering and its consequences to you,
you should read this entire prospectus and any related free writing prospectus authorized by us, including the information referred to
under the heading &ldquo;Risk Factors&rdquo; in this prospectus beginning on page&nbsp;12, and any related free writing prospectus, as
well as the other documents that we incorporate by reference into this prospectus, including our financial statements and the notes to
those financial statements, which are incorporated herein by reference from our&nbsp;Annual Report on Form&nbsp;10-K for the year ended
September&nbsp;30, 2023, filed December&nbsp;7, 2023, as amended on January&nbsp;26, 2024, and our&nbsp;Quarterly Reports on Form&nbsp;10-Q
for the three month periods ended December&nbsp;31, 2023 and March&nbsp;31, 2024, filed on February&nbsp;8, 2024 and May&nbsp;10, 2024,
respectively. Please read &ldquo;Where You Can Find More Information&rdquo; on page&nbsp;26 of this prospectus. Except as otherwise indicated,
all share and per share information in this prospectus gives effect to the reverse stock split of the Company&rsquo;s outstanding common
stock at a ratio of one-for-twenty shares, which was approved by our Board of Directors on April&nbsp;21, 2024 and was effected as of
12:01 a.m.&nbsp;Eastern Time on Thursday, April&nbsp;25, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this prospectus, unless
context requires otherwise, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; or &ldquo;the Company&rdquo; refer to
Applied DNA Sciences,&nbsp;Inc., a Delaware corporation and its consolidated subsidiaries. Our trademarks currently used in the United
States include Applied DNA Sciences&reg;, SigNature&reg; molecular tags, SigNature&reg; T molecular tags, fiberTyping&reg;, SigNify&reg;,
Beacon&reg;, CertainT&reg;, Linea&trade; DNA, Linea&trade; RNAP, Linea&trade; and TR8<SUP>TM</SUP>&nbsp;pharmacogenetic testing. We do
not intend our use or display of other companies&rsquo; trade names or trademarks to imply a relationship with, or endorsement or sponsorship
of us by, any other companies. All trademarks, service marks and trade names included in this prospectus are the property of the respective
owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Applied DNA Sciences,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Company Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biotechnology company
developing and commercializing technologies to produce and detect deoxyribonucleic acid (&ldquo;DNA&rdquo;) and ribonucleic acid (&ldquo;RNA&rdquo;).
Using the polymerase chain reaction (&ldquo;PCR&rdquo;) to enable the production and detection of DNA and RNA, we currently operate in
three primary business markets: (i)&nbsp;the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics
(including biologics and drugs) and, through our recent acquisition of Spindle Biotech,&nbsp;Inc. (&ldquo;Spindle&rdquo;), the development
and sale of a proprietary RNA polymerase (&ldquo;RNAP&rdquo;) for use in the production of messenger RNA (&ldquo;mRNA&rdquo;) therapeutics
(&ldquo;Therapeutic DNA Production Services&rdquo;); (ii)&nbsp;the detection of DNA and RNA in molecular diagnostics and genetic testing
services (&ldquo;MDx Testing Services&rdquo;); and (iii)&nbsp;the manufacture and detection of DNA for industrial supply chain security
services (&ldquo;DNA Tagging and Security Products and Services&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current growth strategy
is to primarily focus our resources on the further development, commercialization, and customer adoption of our Therapeutic DNA Production
Services, including the expansion of our contract development and manufacturing operation (&ldquo;CDMO&rdquo;) for the manufacture of
synthetic DNA for use in the production of nucleic acid-based therapies, and to further expand and commercialize our MDx Testing Services
through genetic testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will continue to update
our business strategy and monitor the use of our resources regarding our various business markets. In addition, we expect that based
on available opportunities and our beliefs regarding future opportunities, we will continue to modify and refine our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Therapeutic DNA Production Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company is developing and commercializing our Linea DNA and Linea IVT platforms for the manufacture of synthetic DNA for use in the production
of nucleic acid-based therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Linea DNA Platform</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
Linea DNA platform is our core enabling technology, and enables the rapid, efficient, and large-scale cell-free manufacture of high-fidelity
DNA sequences for use in the manufacturing of a broad range of nucleic acid-based therapeutics. The Linea DNA platform enzymatically
produces a linear form of DNA we call &ldquo;Linea DNA&rdquo; that is an alternative to plasmid-based DNA manufacturing technologies
that have supplied the DNA used in biotherapeutics for the past 40 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of the first quarter of calendar year 2024, there were 4,002 gene, cell and RNA therapies in development from preclinical through pre-registration
stages, almost all of which use DNA in their manufacturing process. (Source: ASGCT Gene, Cell&nbsp;&amp; RNA Therapy Landscape: Q1 2024
Quarterly Report). Due to what we believe are the Linea DNA platform&rsquo;s numerous advantages over legacy nucleic acid-based therapeutic
manufacturing platforms, we believe this large number of therapies under development represents a substantial market opportunity for
the Linea DNA platform to supplant legacy manufacturing methods in the manufacture of nucleic acid-based therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe our Linea DNA platform holds several important advantages over existing cell-based plasmid DNA manufacturing platforms. Plasmid-based
DNA manufacturing is based on the complex, costly and time-consuming biological process of amplifying DNA in living bacterial cells.
Once amplified, the DNA must be separated from the living cells and other process contaminants via multiple rounds of purification, adding
further complexity and costs. Unlike plasmid-based DNA manufacturing, the Linea DNA platform does not require living cells and instead
amplifies DNA via the enzymatic process of PCR. The Linea DNA platform is simple and can rapidly produce very large quantities of DNA
without the need for complex purification steps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe the key advantages of the Linea DNA platform include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Speed &ndash; Production
    of Linea DNA can be measured in terms of hours, not days and weeks as is the case with plasmid-based DNA manufacturing platforms.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scalability &ndash; Linea
    DNA production takes place on efficient bench-top instruments, allowing for rapid scalability in a minimal footprint.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purity &ndash; DNA produced
    via PCR is pure, resulting in only large quantities of only the target DNA sequence. Unwanted DNA sequences such as the plasmid backbone
    and antibiotic resistance genes, inherent to plasmid DNA, are not present in Linea DNA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simplicity &ndash; The
    production of Linea DNA is streamlined relative to plasmid-based DNA production. Linea DNA requires only four primary ingredients,
    does not require living cells or complex fermentation systems and does not require multiple rounds of purification.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Flexibility &ndash; DNA
    produced via the Linea DNA platform can be easily chemically modified to suit specific customer applications. In addition, the Linea
    DNA platform can produce a wide range of complex DNA sequences that are difficult to produce via plasmid-based DNA production platforms.
    These complex sequences include inverted terminal repeats (&ldquo;ITRs&rdquo;) and long homopolymers such as polyadenylation sequences
    (poly (A)&nbsp;tail) important for gene therapy and mRNA therapies, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Preclinical
studies conducted by the Company have shown that Linea DNA is substitutable for plasmid DNA in numerous nucleic acid-based therapies,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA vaccines;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA templates to produce
    RNA, including mRNA therapeutics; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoptive cell therapy (CAR-T)
    manufacturing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
we believe that Linea DNA is also substitutable for plasmid DNA in the following nucleic acid-based therapies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">viral vector manufacturing
    for&nbsp;<I>in vivo&nbsp;</I>and&nbsp;<I>ex vivo</I>&nbsp;gene editing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clustered regularly interspaced
    short palindromic repeats (&ldquo;CRISPR&rdquo;)-mediated gene therapy; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-viral gene therapy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Linea IVT Platform</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
number of mRNA therapies under development is growing at a rapid rate, thanks in part to the success of the mRNA COVID-19 vaccines. mRNA
therapeutics are produced via a process called&nbsp;<I>in vitro</I>&nbsp;transcription (&ldquo;IVT&rdquo;) that requires DNA as a starting
material. As of the 1st&nbsp;quarter of calendar 2024, there were approximately 450 mRNA therapies under development, with the large
majority of these therapies (67%) in the preclinical stage (Source: ASGCT Gene, Cell&nbsp;&amp; RNA Therapy Landscape: Q1 2024 Quarterly
Report). The Company believes that the mRNA market is in a nascent stage that represents a large growth opportunity for the Company via
the production &nbsp;and supply of DNA critical starting materials and RNAP to produce mRNA therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August&nbsp;2022, the Company launched DNA IVT templates manufactured via its Linea DNA platform and has since secured proof of concept
contracts with numerous mRNA manufacturing customers. In response to this demand, the continued growth of the mRNA therapeutic market,
and the unique abilities of the Linea DNA platform, the Company acquired Spindle in July&nbsp;2023 to potentially increase its mRNA-related
total addressable market (&ldquo;TAM&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Through
our acquisition of Spindle, we launched our Linea IVT platform in July&nbsp;2023, which combines Spindle&rsquo;s proprietary high-performance
RNAP, now marketed by the Company as Linea RNAP, with our enzymatically produced Linea DNA IVT templates. We believe the Linea IVT platform
enables our customers to make better mRNA, faster. Based on data generated by the Company, we believe the integrated Linea IVT platform
offers the following advantages over conventional mRNA production to therapy developers and manufacturers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The prevention or reduction
    of double stranded RNA (&ldquo;dsRNA&rdquo;) contamination resulting in higher target mRNA yields with the potential to reduce downstream
    processing steps. dsRNA is a problematic immunogenic byproduct produced during conventional mRNA manufacture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delivery of IVT templates
    in as little as 14 days for milligram scale and 30 days for gram scale; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced mRNA manufacturing
    complexities; and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potentially enabling mRNA manufactures to produce mRNA
    drug substance in less than 45 days.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the Company&rsquo;s internal modeling, the ability to sell both Linea DNA IVT templates and Linea RNAP under the Linea IVT platform
potentially increases the Company&rsquo;s mRNA-related TAM by approximately 3-5x as compared to selling Linea DNA IVT templates alone,
while also providing a more competitive offering to the mRNA manufacturing market. Currently, Linea RNAP is produced for the Company
under an ISO 13485 quality system by a third-party CDMO located in the United States. The Company is currently undertaking manufacturing
process development work with its Linea RNAP manufacturer to increase production scale of the enzyme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Manufacturing Scale-up</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company plans to offer several quality grades of Linea DNA, each of which will have different permitted uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 33%; border: black 1pt solid; padding: 5pt 4.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quality
    Grade</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 5pt 4.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permitted
    Use</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 5pt 4.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
    Status</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 5pt 4.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLP</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 5pt 4.4pt; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and pre-clinical discovery</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 5pt 4.4pt; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently
    available</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 5pt 4.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMP
    for Starting Materials</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 5pt 4.4pt; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    critical starting materials for the production of mRNA therapies</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 5pt 4.4pt; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Planned
    availability&nbsp;&nbsp;in Q3 of CY2024</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 5pt 4.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMP</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 5pt 4.4pt; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    biologic, drug substance and/or drug product</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 5pt 4.4pt; border-right: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Planned
    availability second half of CY 2025 (1)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">(1)&nbsp;Dependent
on the availability of future financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Company currently manufactures Linea DNA pursuant to Good Laboratory Practices (&ldquo;GLP&rdquo;) and, is creating a fit for purpose
manufacturing facility within our current Stony Brook, NY laboratory space capable of producing Linea DNA IVT templates under Good Manufacturing
Practices (&ldquo;GMP&rdquo;) suitable for use as a critical starting material for clinical and commercial mRNA therapeutics, with a
planned completion date in the third quarter of calendar year 2024 (&ldquo;GMP Site 1&rdquo;). The Company also plans to offer additional
capacity for Linea DNA IVT templates as well as capacity for Linea DNA materials manufactured under GMP suitable for use as, or incorporation
into, a biologic, drug substance and/or drug product, with availability expected during the second half of calendar year 2025, dependent
upon the availability of future funding (&ldquo;GMP Site 2&rdquo;). GMP is a quality standard used globally and by the U.S. Food and
Drug Administration (&ldquo;FDA&rdquo;) to ensure pharmaceutical quality. &nbsp;Drug substances are the pharmaceutically active components
of drug products. According to the Company&rsquo;s internal modeling using currently projected unit pricing based on current pricing
and market analysis, the Company believes that GMP Site 1 affords the Company a potential annual revenue opportunity of up to $20M at
full capacity utilization, and GMP Site 2 affords the Company a potential annual revenue opportunity of up to $63M at full capacity utilization.
This potential revenue opportunity may not be realized and is not indicative of profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Segment Business
Strategy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
business strategy for our Therapeutic DNA Production Services is to capitalize upon the rapid growth of mRNA therapies in the near term
via our planned near term future availability of Linea DNA IVT templates manufactured under GMP at our GMP Site 1, while at the same
time laying the basis for additional clinical and commercial applications of Linea DNA with our future planned availability of Linea
DNA manufactured under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product at planned GMP
Site 2. Planned GMP Site 2 may also be used for additional Linea DNA IVT template manufacturing if customer demand exceeds the capacity
of GMP Site 1. Our current plan is: (i)&nbsp;through our Linea IVT platform and planned near term future GMP manufacturing capabilities
for IVT templates at GMP Site 1 to secure commercial-scale supply contracts with clinical and commercial mRNA and/or self-amplifying
mRNA (&ldquo;sa-RNA&rdquo;) manufacturers for Linea DNA IVT templates and/or Linea RNAP as critical starting materials; (ii)&nbsp;to
utilize our current GLP production capacity for non-IVT template applications to secure supply and/or development contracts with pre-clinical
therapy developers that use DNA in their therapy manufacturing, and (iii)&nbsp;upon our development of our planned future Linea DNA production
under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product at planned GMP Site 2, to convert
existing and new Linea DNA customers into large-scale supply &nbsp;contracts to supply Linea DNA for clinical and commercial use as,
or incorporation into, a biologic, drug substance and/or drug product in a wide range of nucleic acid therapies. Until we complete our
GMP Site 1 to produce DNA critical starting materials (DNA IVT templates) for mRNA manufacturing, we will not be able to realize significant
revenues from this business. We estimate the cost of creating GMP Site 1 will be approximately $1.5 million. If we were to expand our
facilities to enable GMP production of Linea DNA for use as, or incorporation, into a biologic, drug substance and/or drug product as
planned for GMP Site 2, the cost may be up to approximately $10 million which would require additional funding. We are currently building
GMP Site 1 within our existing laboratory space. We anticipate that GMP Site 2 would require us to acquire additional space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, we plan to leverage our Therapeutic DNA Production Services and deep knowledge of PCR to develop and monetize, ourselves or
with strategic partners, one or more Linea DNA-based therapeutic or prophylactic vaccines for high-value veterinary health indications
(collectively &ldquo;Linea DNA Vaccines&rdquo;). We currently seek to commercialize our Linea DNA Vaccines in conjunction with lipid
nanoparticle (&ldquo;LNP&rdquo;) encapsulation to facilitate intramuscular (&ldquo;IM&rdquo;) administration. We have recently demonstrated&nbsp;<I>in
vitro</I>&nbsp;and&nbsp;<I>in vivo</I>&nbsp;(mice studies) expression of generic reporter proteins via Linea DNA encapsulated by LNPs.
For the&nbsp;<I>in vivo</I>&nbsp;study, successful expression of the LNP-encapsulated Linea DNA was administered and achieved via IM
injection. We believe that our Linea DNA Vaccines under development provide a substantial advantage over plasmid DNA-based vaccines for
the veterinary health market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>MDx Testing Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Through
ADCL, we leverage our expertise in DNA and RNA detection via PCR to provide and develop clinical molecular diagnostics and genetic (collectively
 &ldquo;MDx&rdquo;) testing services. ADCL is a NYSDOH clinical laboratory improvement amendments-certified laboratory which is currently
permitted for virology. Permitting for genetics (molecular) is currently pending with the NYSDOH. In providing MDx Testing Services,
ADCL employs its own or third-party molecular diagnostic tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have successfully validated internally our pharmacogenomics testing services (the &ldquo;PGx Testing Services&rdquo;). Our PGx Testing
Services will utilize a 120-target PGx panel test to evaluate the unique genotype of a specific patient to help guide the patient&rsquo;s
healthcare provider in making individual drug therapy decisions. Our PGx Testing Services are designed to interrogate DNA targets on
over 33 genes and provide genotyping information relevant to certain cardiac, mental health, oncology, and pain management drug therapies.
Our PGx Testing Services cannot commence until we receive approval from the NYSDOH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March&nbsp;22, 2023, we submitted our validation package to the NYSDOH for our PGx Testing Services. On September&nbsp;21, 2023, we received
a first set of comments from NYSDOH requesting additional data and clarifications. A response was submitted to NYSDOH on November&nbsp;17,
2023. &nbsp;On December&nbsp;26, 2023, we received a second set of comments from NYSDOH requesting additional data and clarifications
to which a response was submitted on February&nbsp;23, 2024. A third set of comments was received from NYSDOH on March&nbsp;29, 2024.
A response must be filed by May&nbsp;28, 2024.&nbsp;Currently, the timing of any approval by NYSDOH for our PGx Testing Services is unclear.
Recently published studies show that population-scale PGx enabled medication management can significantly reduce overall population healthcare
costs, reduce adverse drug events, and increase overall population wellbeing. These benefits can result in significant cost savings to
large entities and self-insured employers, the latter accounting for approximately 65% of all U.S. employers in 2022. If and when approved
by the NYSDOH, we plan to leverage our PGx Testing Services to provide PGx testing services to large entities, self-insured employers
and healthcare providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Historically,
the majority of our revenue attributable to our MDx Testing Services has been derived from our safeCircle&reg; COVID-19 testing solutions,
for which testing demand has significantly declined commencing in our fiscal third quarter of 2023, resulting in substantially reduced
revenues. We expect future demand for COVID-19 testing to continue to be reduced and we may terminate COVID-19 testing services in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>DNA Tagging and Security Products and
Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">By
leveraging our expertise in both the manufacture and detection of DNA via PCR, our DNA Tagging and Security Products and Services allow
our customers to use non-biologic DNA tags manufactured on our Linea DNA platform to mark objects in a unique manner and then identify
these objects by detecting the absence or presence of the DNA tag. The Company&rsquo;s core DNA Tagging and Security Products and Services,
which are marketed collectively as a platform under the trademark CertainT&reg;, include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SigNature&reg; Molecular
    Tags, which are short non-biologic DNA taggants produced by the Company&rsquo;s Linea DNA platform, provide a methodology to authenticate
    goods within large and complex supply chains with a focus on cotton, nutraceuticals and other products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SigNify&reg; portable DNA
    readers and SigNify consumable reagent test kits provide definitive real-time authentication of the Company&rsquo;s DNA tags in the
    field.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fiberTyping&reg; and other
    product genotyping services use PCR-based DNA detection to determine a cotton species or cultivar, via a product&rsquo;s naturally
    occurring DNA sequence for the purposes of product provenance authentication.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isotopic analysis testing
    services, provided in partnership with third-party labs, use cotton&rsquo;s carbon, hydrogen and oxygen elements to indicate origin
    of its fiber through finished goods.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
date, our largest commercial application for our DNA Tagging and Security Products and Services is in the tracking and provenance authentication
of cotton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
business plan is to leverage consumer and governmental awareness for product traceability to expand our existing partnerships and seek
new partnerships for our DNA Tagging and Security Products and Services with a focus on cotton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>FDA Publishes Final Rule&nbsp;on Laboratory
Developed Tests</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
an LDT, our MDx Testing Services are currently subject to enforcement discretion by the FDA. &nbsp;On April&nbsp;29, 2024, however, the
FDA published a final rule&nbsp;on LDTs, in which FDA outlines its plans to end enforcement discretion for many LDTs in five stages over
a four-year period. &nbsp;In Phase 1 (effective May&nbsp;6, 2025), clinical laboratories running LDTs will be required to comply with
medical device (adverse event) reporting and correction/removal reporting requirements, as well as requirements for maintenance of complaint
files under the FDA&rsquo;s quality systems regulation (QSR). &nbsp;In Phase 2 (effective May&nbsp;6, 2026), clinical laboratories will
be required to comply with all other device requirements (e.g., registration/listing, labeling, investigational use), except for the
remaining QSR requirements and premarket review. &nbsp;In Phase 3 (effective May&nbsp;6, 2027), clinical laboratories will be required
to comply with all remaining QSR requirements. &nbsp;In Phase 4 (effective ~November&nbsp;6, 2027), clinical laboratories will be required
to comply with premarket review requirements for high-risk tests (<I>i.e.</I>, tests subject to the premarket approval (PMA) requirement).
 &nbsp;Finally, in Phase 5 (effective May&nbsp;6, 2028), clinical laboratories will be required to comply with premarket review requirements
for moderate- and low-risk tests (<I>i.e.</I>, tests subject to the&nbsp;<I>de novo</I>&nbsp;or 510(k)&nbsp;requirement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the final rule, several types of tests will be eligible for some degree of continued enforcement discretion, including LDTs approved
by NYSDOH. FDA notes, however, that it retains discretion to pursue enforcement action for violations of the FDCA at any time and intends
to do so when appropriate. FDA further explains that it may update any of the enforcement discretion policies set forth in the final
rule&nbsp;as circumstances warrant or if the circumstances that inform those policies change, consistent with FDA&rsquo;s good guidance
practices. Based on our current analysis of the FDA final rule, and assuming the final rule&nbsp;goes into effect without modification,
we believe that ADCL&rsquo;s current and future NYSDOH approved LDTs, which includes our under development PGx Testing Services, will
be exempt from FDA premarket review requirements but will remain subject to the requirements of Phases 1 through 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Special Meeting of Stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&nbsp;15, 2024, we
held a special meeting of stockholders (the &ldquo;Special Meeting&rdquo;) pursuant to which our stockholders approved the following:
(i)&nbsp;in accordance with Nasdaq Listing Rule&nbsp;5635(d), the issuance to certain holders of common stock purchase warrants in connection
with a private placement; (ii)&nbsp;in accordance with Nasdaq Listing Rule&nbsp;5635(d), the repricing of certain of our common stock
purchase warrants; (iii)&nbsp;a grant of discretionary authority to the Board of Directors giving them the authority to amend the Company&rsquo;s
certificate of incorporation, as amended, to effect a reverse stock split of common stock, at a ratio in the range from one-for-five
to one-for-fifty, with such specific ratio to be determined by the Company&rsquo;s Board of Directors following the Special Meeting (the
 &ldquo;Reverse Split Proposal&rdquo;) in order to regain compliance with the requirement to maintain a minimum bid price of $1.00 per
share for continued listing on Nasdaq, as set forth in the Nasdaq Listing Rule&nbsp;5550(a)(2)&nbsp;(the &ldquo;Minimum Bid Price Requirement&rdquo;);
and (iv)&nbsp;an amendment to the Company&rsquo;s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock
reserved for issuance by 200,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Reverse Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed above, on April&nbsp;15,
2024, we held the Special Meeting where our stockholders approved the Reverse Split Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The reverse stock split was
effected at 12:01 a.m.&nbsp;Eastern Time on Thursday, April&nbsp;25, 2024 and combined each twenty shares of our outstanding common stock
into one share of common stock, without any change in the par value per share. Moreover, the reverse stock split correspondingly adjusted,
(i)&nbsp;the per share exercise price and the number of shares issuable upon the exercise of all outstanding options, and (ii)&nbsp;the
number of shares underlying any of our outstanding warrants by adjusting the conversion ratio for each instrument and increasing the
applicable exercise price or conversion price in accordance with the terms of each instrument and based on the reverse stock split ratio.
No fractional shares were issued in connection with the reverse stock split. Any fractional shares resulting from the reverse stock split
were rounded up to the nearest whole share. The reverse stock split resulted in a reduction of our outstanding shares of common stock
from 17,261,343 to 863,068 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Nasdaq Notification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May&nbsp;9, 2024, the
Company received a written notification from the Listing Qualifications Department (the &ldquo;Staff&rdquo;) of The Nasdaq Stock Market
LLC (&ldquo;Nasdaq&rdquo;) notifying the Company that the closing bid price of its common stock had exceeded $1.00 per share for 10 consecutive
trading days, and as a result, the Company had regained compliance with the Minimum Bid Price Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May&nbsp;16, 2024, the
Company received a deficiency letter (the &ldquo;Letter&rdquo;) from the Nasdaq Staff notifying the Company that it is not in compliance
with the minimum stockholders&rsquo; equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market pursuant
to Nasdaq Listing Rule&nbsp;5550(b)(1)&nbsp;(the &ldquo;Stockholders&rsquo; Equity Requirement&rdquo;). In the Company&rsquo;s Quarterly
Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2024, the Company reported stockholders&rsquo; equity of ($175,385), which
was below the Stockholders&rsquo; Equity Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Nasdaq
rules, the Company has 45 calendar days, or until July&nbsp;1, 2024, to submit a plan to the Staff to regain compliance (the &ldquo;Compliance
Plan&rdquo;) with the Stockholders&rsquo; Equity Requirement. If the Compliance Plan is accepted, Nasdaq can grant an extension of up
to 180 calendar days from the date of the Letter for the Company to evidence compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company must submit a
Compliance Plan to the Staff on or before July&nbsp;1, 2024 and is considering available options to regain compliance with the Stockholders&rsquo;
Equity Requirement. However, there is no assurance that the Company will be successful in developing the Compliance Plan, that the Compliance
Plan will be accepted by Nasdaq, or even if it is accepted, that the Company will ultimately be able to regain compliance with the Stockholders&rsquo;
Equity Requirement within the allotted extension period, which may be less than 180 calendar days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Receipt of the Letter described
above from Nasdaq has no immediate effect on the listing of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Delaware corporation,
which was initially formed in 1983 under the laws of the State of Florida as Datalink Systems,&nbsp;Inc. In 1998, we reincorporated in
the State of Nevada, and in 2002, we changed our name to our current name, Applied DNA Sciences,&nbsp;Inc. On December&nbsp;17, 2008,
we reincorporated from the State of Nevada to the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
are located at the Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York, where we have established
laboratories for the manufacture and detection of nucleic acids (DNA and RNA) to support our various business units. In addition, this
location also houses our NYSDOH CLEP-permitted, Clinical Laboratory Improvement Amendments (&ldquo;CLIA&rdquo;)-certified clinical laboratory
where we perform MDx Testing Services. The mailing address of our corporate headquarters is 50 Health Sciences Drive, Stony Brook, New
York 11790, and our telephone number is (631) 240-8800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a &ldquo;smaller reporting
company&rdquo; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage
of certain of the scaled disclosures available to smaller reporting companies. We will continue to be a &ldquo;smaller reporting company&rdquo;
until we have $250&nbsp;million or more in public float (based on our common stock) measured as of the last business day of our most
recently completed second fiscal quarter or, in the event we have no&nbsp;public float (based on our common stock) or a public float
(based on our common stock) that is less than $700&nbsp;million, annual revenues of $100&nbsp;million or more during the most recently
completed fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may choose to take advantage
of some, but not all, of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly,
the information contained herein may be different from the information you receive from other public companies in which you hold stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risk Factor Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary does not address all of the risks
that we face. Additional discussions of the risks summarized in this risk factor summary, and other risks that we face, can be found
below and should be carefully considered, together with other information in this prospectus and the documents incorporated by reference
herein before making investment decisions.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have produced limited
    revenue. This makes it difficult to evaluate our future prospects and increase the risk that we will not be successful.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial doubt
    relating to our ability to continue as a going concern.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our opportunities to work
    with customers to develop pharmaceuticals and biologics will require substantial additional funding. Our customers may not be successful
    in their efforts to create a pipeline of product candidates, to develop commercially successful products, or to develop commercially
    successful biologic production.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not successfully
    implement our business strategies, including achieving our growth objectives.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may require additional
    financing which may in turn require the issuance of additional shares of common stock, preferred stock or other debt or equity securities
    (including convertible securities) and which would dilute the ownership held by or stockholders.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operating results have
    been and could be adversely affected by a reduction in business with our significant customers.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may encounter difficulties
    in managing our growth and these difficulties could impair our profitability.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current emphasis on
    Therapeutic DNA Production Services may reduce our ability to maintain and expand our existing MDX Testing Services and DNA Tagging
    and Security Products and Services businesses.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If in the future our MDX
    Testing Services and DNA Tagging and Security Products and Services businesses do not generate significant cash flows, we may not
    have sufficient capital to develop, commercialize and have our customers adopt our Therapeutic DNA Production Services.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to expand
    our DNA manufacturing capacity, we could lose revenue and our business could suffer.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapidly changing technology
    and extensive competition in synthetic biology could make the services or products we are developing obsolete or non-competitive
    unless we continue to develop new and improved services or products and pursue new market opportunities.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical, diagnostic
    and biologic products and/or services are highly complex, and if we or our collaborators and customers are unable to provide quality
    and timely offerings to our respective customers, our business could suffer.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to develop
    and maintain manufacturing facilities that meet GMP.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical and biologic-related
    revenue will be dependent on our collaborators&rsquo; and customers&rsquo; demand for our manufacturing services.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to consistently
    manufacture or source our products to the necessary specifications or in quantities necessary to meet demand on a timely basis and
    at acceptable performance and cost levels.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The markets for drug and
    biologic candidates and synthetic DNA are very competitive, and we may be unable to continue to compete effectively in these industries
    in the future.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The markets for our supply
    chain security and product authentication solutions are very competitive, and we may be unable to continue to compete effectively
    in these industries in the future.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We compete with life science,
    pharmaceutical and biotechnology companies, some of whom are our customers, who are substantially larger than we are and potentially
    capable of developing new approaches that could make our products and technology obsolete or develop their own internal capabilities
    that compete with our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our intellectual property
    rights are valuable, and any inability to protect them could reduce the value of our products, services and brand.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical and biologic-related
    revenue is generally dependent on regulatory approval, oversight and compliance.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the FDA were to begin
    to enforce regulation of laboratory-developed tests (&ldquo;LDTs&rdquo;), we could incur substantial costs and delays associated
    with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements in respect
    of MDx Testing Services.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with
    laboratory licensing requirements, we could lose the ability to offer our MDx Testing Services or experience disruptions to our business.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with
    healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to continue
    to retain the services of Dr.&nbsp;Hayward, we may not be able to continue our operations.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may have conflicts of
    interest with our affiliates and related parties, and in the past we have engaged in transactions and entered into agreements with
    affiliates that were not negotiated at arms&rsquo; length.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are a large number
    of shares of common stock underlying our outstanding options and warrants and the sale of these shares may depress the market price
    of our common stock and cause immediate and substantial dilution to our existing stockholders.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have received a deficiency
    letter from the Nasdaq Staff notifying us that we are not in compliance with the minimum stockholders&rsquo; equity requirement of
    at least $2,500,000 for continued inclusion on The Nasdaq Capital Market and no assurance can be given that we will be able to maintain
    our Nasdaq listing.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reverse stock split
    to regain compliance with Nasdaq&rsquo;s Minimum Bid Price Requirement, which was effected on Thursday, April&nbsp;25, 2024, may
    adversely impact the market price of our common stock.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reverse stock split
    may decrease the liquidity of our common stock and as a result our common stock may not satisfy the investing requirements of new
    investors, including institutional investors.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effective increase
    in the number of shares of our common stock available for issuance as a result of our reverse stock split could result in further
    dilution to our existing stockholders and have anti-takeover implications.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the above
    key factors, as well as other variables affecting our operating results and financial condition, past financial performance may not
    be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future
    periods.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><FONT STYLE="text-transform: uppercase"><B>Summary
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units being
    offered</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 71%; text-align: justify">9,230,769 Units at the public offering price of $1.30 per Unit
    on a &ldquo;best-efforts&rdquo; basis. Each Unit will consist of one share of common stock (or Pre-Funded Warrant to purchase one
    share of our common stock in lieu thereof), one Series&nbsp;A Warrant to purchase one share of common stock and one Series&nbsp;B
    Warrant to purchase one share of common stock. The Units have no stand-alone rights and will not be certificated or issued as stand-alone
    securities. The shares of common stock and Pre-Funded Warrants, if any, can each be purchased in this offering only with the accompanying
    Series&nbsp;A Warrants and Series&nbsp;B Warrants as part of Units, but the components of the Units will be immediately separable
    and will be issued separately in this offering.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units, including Pre-Funded
    Warrants, offered by us in this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are also offering to each purchaser whose purchase of Units consisting of shares of common stock in this offering would otherwise
    result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the
    election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity
    to purchase, if the purchaser so chooses, Units, including Pre-Funded Warrants, in lieu of shares of common stock that would otherwise
    result in the purchaser&rsquo;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding
    common stock. Subject to limited exceptions, a holder of Pre-Funded Warrants will not have the right to exercise any portion of its
    Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of
    the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each Pre-Funded
    Warrant will be exercisable for one share of our common stock. The purchase price of each Unit including a Pre-Funded Warrant will
    equal the price per Unit in which the shares of common stock and accompanying Series&nbsp;Warrants are being sold to the public in
    this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant will be $0.0001 per share. The Pre-Funded Warrants
    are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. This offering
    also relates to the shares of common stock issuable upon exercise of any Pre-Funded Warrants sold in this offering. For each Pre-Funded
    Warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Series&nbsp;Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Unit includes one
    share of common stock, or one Pre-Funded Warrant in lieu of one share of common stock, one Series&nbsp;A Warrant and one Series&nbsp;B
    Warrant. Each Series&nbsp;A Warrant will become exercisable beginning on the date of the Warrant Stockholder Approval at a price
    of $</FONT>1.99 per share and will expire five years from the date of Warrant Stockholder Approval, and each Series&nbsp;B Warrant
    will become exercisable beginning on the date of the Warrant Stockholder Approval at a price of $1.99 per share, or pursuant to an
    alternate cashless exercise option, and will expire one year from the date of Warrant Stockholder Approval. The Series&nbsp;B Warrants
    contain an alternative cashless exercise option, the Series&nbsp;A Warrants contain certain anti-dilution provisions and both the
    Series&nbsp;A and Series&nbsp;B Warrants contain a reverse stock split provision which requires the Company to effect a reverse stock
    split under certain circumstances. See &ldquo;Description of Securities &mdash; Series&nbsp;Warrants.&rdquo; This prospectus also
    relates to the offering of the shares of common stock issuable upon exercise of the Series&nbsp;Warrants.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Placement Agent Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to this prospectus,
    we will issue to the Co-Placement Agents (or their respective designees) warrants to purchase shares equal to 5.0% of the number
    of Units being offered in this offering at an exercise price equal to that of the Series&nbsp;Warrants and with an expiration date
    of five years from the commencement of sales as part of the compensation payable to the Co-Placement Agents in connection with this
    offering (the &ldquo;Placement Agent Warrants&rdquo;). See &ldquo;Plan of Distribution&rdquo; on page&nbsp;23 of this prospectus.
    This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the Placement Agent Warrants.
    &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock outstanding prior to this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">984,728 shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock to be outstanding after this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">10,215,497 shares (assuming no sale of any Pre-Funded Warrants and assuming none of the Series&nbsp;Warrants
    or Placement Agent Warrants issued in this offering are exercised).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 71%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that the net proceeds to us from this offering will be approximately $10.8 million, after deducting the Placement Agent
    fees and estimated offering expenses payable by us and assuming no exercise of the Series&nbsp;Warrants. We intend to use the net
    proceeds from the sale of the securities for the further development of our Therapeutic DNA Production and MDx Testing Services,
    as well as general corporate purposes, which may include research and development expenses, capital expenditures, working capital
    and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that
    complement our business, although we have no present commitments or agreements to make any such acquisitions or investments as of
    the date of this prospectus. Pending these uses, we intend to invest the funds in short-term, investment grade, interest-bearing
    securities. It is possible that, pending their use, we may invest the net proceeds in a way that does not yield a favorable, or any,
    return for us. See &ldquo;Use of Proceeds&rdquo; on page&nbsp;16 of this prospectus.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    should carefully read and consider the information set forth under &ldquo;Risk Factors&rdquo; on page&nbsp;12 of this prospectus
    and the documents incorporated by reference herein before deciding to invest in our securities.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up agreements</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of our executive officers and directors will enter into lock-up agreements in connection with the offering. Under these agreements,
    each of these persons may not, without the prior written approval of Craig-Hallum, offer, sell, contract to sell or otherwise dispose
    of or hedge common stock or securities convertible into or exchangeable for common stock, subject to certain exceptions. The restrictions
    contained in these agreements will be in effect for a period of 90 days after the date of the closing of this offering.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, we have agreed to be subject to a lock-up period of one year following the date of closing of the offering pursuant to
    this prospectus. This means that, during the applicable lock-up period, we may not offer, sell, contract to sell or otherwise dispose
    of or hedge common stock or securities convertible into or exchangeable for common stock, subject to customary exceptions. However,
    this lock-up period shall terminate upon the earlier of 90 days after (i)&nbsp;the closing of this offering if the Warrant Stockholder
    Approval is obtained prior to 90 days after the closing of this offering and (ii)&nbsp;the date that Warrant Stockholder Approval
    is obtained. For more information, see &ldquo;Plan of Distribution&rdquo; on page&nbsp;23&nbsp;of this prospectus.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market for common stock</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is listed
    on The Nasdaq Capital Market under the symbol &ldquo;APDN.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing of Pre-Funded Warrants and Series&nbsp;Warrants</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not intend to list
    the Pre-Funded Warrants or the Series&nbsp;Warrants on any securities exchange or nationally recognized trading system. Without a
    trading market, the liquidity of the Pre-Funded Warrants and Series&nbsp;Warrants will be extremely limited.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of our
common stock to be outstanding after this offering is based on &#8239;984,728 shares of our common stock outstanding as of May&nbsp;24,
2024, and excludes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109,363&nbsp;shares
    of common stock issuable upon exercise of options outstanding as of May&nbsp;24, 2024, with a weighted average exercise price of
    $185.00 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">825,067 shares
    of common stock issuable upon exercise of warrants outstanding as of May&nbsp;24, 2024, with a weighted average exercise price of
    $20.81 per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,355 shares
    of common stock reserved for future grant or issuance as of May&nbsp;24, 2024, under our equity incentive plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="text-transform: uppercase"><B>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investment
in our securities, including our common stock, Series&nbsp;Warrants, and Pre-Funded Warrants, involves a high degree of risk. In addition
to the risks and investment considerations discussed elsewhere in this prospectus, any document incorporated by reference herein or any
 &ldquo;free writing prospectus&rdquo; we have authorized in connection with this offering, the following factors should be carefully
considered by anyone purchasing the securities offered by this prospectus. The risks and uncertainties described below are not the only
ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business
operations. We also update risk factors from time to time in our periodic reports on </I></FONT><I><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000114420419018217/tv518228_10-ka.htm" STYLE="-sec-extract: exhibit">Forms 10-K</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/744452/000114420419039521/tv526857_10q.htm" STYLE="-sec-extract: exhibit">10-Q</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/744452/000114420419041661/tv528207_8k.htm" STYLE="-sec-extract: exhibit">8-K</A> which will
be incorporated by reference in this prospectus. If any of the following risks actually occur, our business could be harmed. In such
case, the trading price of our common stock could decline and investors could lose all or a part of their investment. All of these risks
could adversely affect our business, business prospects, results of operations, financial condition and cash flows.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>See also the statements
contained under the heading &ldquo;Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>There is substantial
doubt relating to our ability to continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have recurring net losses, which have resulted in an accumulated deficit of $308,255,808 as of March&nbsp;31, 2024. We have incurred
a net loss of $5,624,064 for the six months ended March&nbsp;31, 2024. At March&nbsp;31, 2024, we had cash and cash equivalents of $3,149,640.
We have concluded that these factors raise substantial doubt about our ability to continue as a going concern for one year from the issuance
of the financial statements. We will continue to seek to raise additional working capital through public equity, private equity or debt
financings. If we fail to raise additional working capital, or do so on commercially unfavorable terms, it would materially and adversely
affect our business, prospects, financial condition and results of operations, and we may be unable to continue as a going concern. &nbsp;If
we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue
as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable
terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We have received
a deficiency letter from the Nasdaq Staff notifying us that we are not in compliance with the minimum stockholders&rsquo; equity requirement
of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market and no assurance can be given that we will be able to maintain
our Nasdaq listing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May&nbsp;16, 2024, we received a deficiency letter from the Nasdaq Staff notifying us that we are not in compliance with the minimum
stockholders&rsquo; equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq
Listing Rule&nbsp;5550(b)(1)&nbsp;(the &ldquo;Stockholders&rsquo; Equity Requirement&rdquo;). In our Quarterly Report on Form&nbsp;10-Q
for the quarter ended March&nbsp;31, 2024, we reported stockholders&rsquo; equity of ($175,385), which was below the Stockholders&rsquo;
Equity Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
accordance with Nasdaq rules, we have 45 calendar days, or until July&nbsp;1, 2024, to submit a plan to the Staff to regain compliance
(the &ldquo;Compliance Plan&rdquo;) with the Stockholders&rsquo; Equity Requirement. If the Compliance Plan is accepted, Nasdaq can grant
an extension of up to 180 calendar days from the date of the deficiency letter for the Company to evidence compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company must submit a Compliance Plan to the Staff on or before July&nbsp;1, 2024 and is considering available options to regain compliance
with the Stockholders&rsquo; Equity Requirement. However, there is no assurance that the Company will be successful in developing the
Compliance Plan, that the Compliance Plan will be accepted by Nasdaq, or even if it is accepted, that the Company will ultimately be
able to regain compliance with the Stockholders&rsquo; Equity Requirement within the allotted extension period, which may be less than
180 calendar days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Receipt
of the Letter described above from Nasdaq has no immediate effect on the listing of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
there can be no assurance that we will continue to meet Nasdaq&rsquo;s other continued listing requirements. Our failure to meet such
applicable listing criteria could result in the termination of the listing of our common stock on Nasdaq. In the event we are unable
to have our shares traded on Nasdaq, our common stock could potentially trade on the OTCQX or the OTCQB, each of which is generally considered
less liquid and more volatile than Nasdaq. Failure to maintain our listing on Nasdaq or on another national securities exchange could
make it more difficult to trade our shares, could prevent our common stock from trading on a frequent and liquid basis, and could result
in the market price of our common stock being less than it would be if we maintained our listing on Nasdaq or on another national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Reverse Stock Split:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We approved a reverse stock split to regain
compliance with Nasdaq&rsquo;s Minimum Bid Price Requirement, which was effected on Thursday, April&nbsp;25, 2024 and which may adversely
impact the market price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;1, 2023,
we received a written notice (the &ldquo;Notification Letter&rdquo;) from Nasdaq&rsquo;s Listing Qualifications Department notifying
us that, based upon the closing bid price of our common stock for the last 30 consecutive business days, we were not in compliance with
the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in the Nasdaq Listing
Rule&nbsp;5550(a)(2)&nbsp;(the &ldquo;Minimum Bid Price Requirement&rdquo;), and that, if at any time before May&nbsp;29, 2024, the closing
bid price of our common stock remained at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq would provide
written notification that we had regained compliance with the Minimum Bid Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&nbsp;15, 2024, our
stockholders approved the proposal in the Company&rsquo;s Definitive Proxy Statement dated March&nbsp;14, 2024 to grant discretionary
authority to the Board of Directors to amend the Company&rsquo;s Certificate of Incorporation to effect a reverse stock split within
a range of one-for-five to one-for-fifty, if needed to meet the Minimum Bid Price Requirement<FONT STYLE="background-color: white">.&nbsp;</FONT>Subsequently,
on April&nbsp;21, 2024, our Board of Directors approved a reverse stock split at a ratio of one-for-twenty shares, which was effected
at 12:01 a.m.&nbsp;Eastern Time on Thursday, April&nbsp;25, 2024. On May&nbsp;9, 2024, the Company received a written notification from
Nasdaq&rsquo;s Listing Qualifications Department notifying the Company that the closing bid price of its common stock had exceeded $1.00
per share for 10 consecutive trading days, and as a result, the Company had regained compliance with the Minimum Bid Price Requirement.
There can be no assurance that our common stock will maintain market prices consistent with such reverse stock split and that we will
remain in compliance with the Minimum Bid Price Requirement or any other Nasdaq continued listing requirement, and it is possible that
the market price of our common stock will decline more than would have occurred in the absence of a reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The reverse stock split may decrease the
liquidity of the shares of our common stock and the resulting market price of our common stock may not attract or satisfy the investing
requirements of new investors, including institutional investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The liquidity of the shares
of our common stock may be affected adversely by the reverse stock split given the reduced number of shares outstanding following the
reverse stock split. Additionally, the reverse stock split may increase the number of shareholders who own odd lots (less than 100 shares)
of our common stock, creating the potential for such shareholders to experience an increase in the cost of selling their shares and greater
difficulty affecting such sales. Moreover, there can be no assurance that the reverse stock split will result in a share price that will
attract new investors, including institutional investors, and there can be no assurance that the market price of our common stock will
satisfy the investing requirements of these investors. Consequently, the trading liquidity of our common stock may not necessarily improve
as a result of the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The effective increase in the number of
shares of our common stock available for issuance as a result of the reverse stock split may result in further dilution to our existing
stockholders and have anti-takeover implications.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The reverse stock split alone
had no effect on our authorized capital stock, and the total number of authorized shares remains the same as before the reverse stock
split. The reverse stock split of our issued and outstanding shares increased the number of shares of our common stock (or securities
convertible or exchangeable for our common stock) available for issuance. The additional available shares are available for issuance
from time to time at the discretion of the Company&rsquo;s Board of Directors when opportunities arise, without further stockholder action
or the related delays and expenses, except as may be required for a particular transaction by law, the rules&nbsp;of any exchange on
which our securities may then be listed, or other agreements or restrictions. Any issuance of additional shares of our common stock would
increase the number of outstanding shares of our common stock and (unless such issuance was pro-rata among existing stockholders) the&nbsp;percentage
ownership of existing stockholders would be diluted accordingly. In addition, any such issuance of additional shares of our common stock
could have the effect of diluting the earnings per share and book value per share of outstanding shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the effective
increase in the number of authorized shares could, under certain circumstances, have anti-takeover implications. For example, the additional
shares of common stock that have become available for issuance could be used by us to oppose a hostile takeover attempt or to delay or
prevent changes in control or our management. Although our reverse stock split is prompted by other considerations and not by the threat
of any hostile takeover attempt, stockholders should be aware that our reverse stock split could facilitate future efforts by us to deter
or prevent changes in control, including transactions in which our stockholders might otherwise receive a premium for their shares over
then-current market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may need
to effect an additional reverse stock split as a result of this offering. If at any time the Series&nbsp;A Warrants or Series&nbsp;B
Warrants are outstanding and the Company receives notice from the Nasdaq Listing Qualifications Department that the Company is failing
to satisfy the $1.00 minimum bid requirement (the &ldquo;<U>Trigger </U>Date&rdquo;), then the Company has covenanted to take all necessary
steps to obtain the necessary consents and approvals to undertake a reverse stock split after such Trigger Date and shall, prior to the
effectiveness of any delisting notice issued by Nasdaq, effect such reverse stock split. Any such issuance of additional shares of our
common stock could have the effect of diluting the earnings per share and book value per share of outstanding shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20"><B><I>This is a best-efforts
offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for
our business plans, including our near-term business plans.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #231f20">The Co-Placement
Agents have agreed to use their best efforts to solicit offers to purchase the securities in this offering. The Co-Placement Agents have
no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of
the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because
there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent
fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth herein. We may
sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors
in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued
operations, including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our
operations in the short-term and may need to raise additional funds to complete such short-term operations. Such additional fundraises
may not be available or available on terms acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Management will have broad discretion as
to the use of proceeds from this offering and we may use the net proceeds in ways with which you may disagree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net
proceeds of this offering for the further development of our Therapeutic DNA Production and MDx Testing Services, as well as general
corporate purposes, which may include research and development expenses, capital expenditures, working capital and general and administrative
expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our business, although
we have no present commitments or agreements to make any such acquisitions or investments as of the date of this prospectus. Our management
will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not
improve our results of operations or enhance the value of our common stock. Accordingly, you will be relying on the judgment of our management
on the use of net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds
are being used appropriately. Our failure to apply these funds effectively could have a material adverse effect on our business and cause
the price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending these uses, we intend
to invest the funds in short-term, investment grade, interest-bearing securities. It is possible that, pending their use, we may invest
the net proceeds in a way that does not yield a favorable, or any, return for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The public offering price was set by
our Board of Directors and does not necessarily indicate the actual or market value of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has approved the public offering price and other terms of this offering after considering, among other things: the number of shares authorized
in our Certificate of Incorporation; the current market price of our common stock; trading prices of our common stock over time; the
volatility of our common stock; our current financial condition and the prospects for our future cash flows; the availability of and
likely cost of capital of other potential sources of capital; the characteristics of interested investors and market and economic conditions
at the time of the offering. The public offering price is not intended to bear any relationship to the book value of our assets or our
past operations, cash flows, losses, financial condition, net worth or any other established criteria used to value securities. The public
offering price may not be indicative of the fair value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may experience dilution as a result
of future equity issuances.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The issuance of additional shares of our common stock in future offerings could be dilutive to stockholders if they do
not invest in future offerings. Moreover, to the extent that we issue options or warrants to purchase, or securities convertible into
or exchangeable for, shares of our common stock in the future and those options, warrants or other securities are exercised, converted
or exchanged, stockholders may experience further dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the Pre-Funded
Warrants or Series&nbsp;Warrants being offered in this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no established public
trading market for the Pre-Funded Warrants or Series&nbsp;Warrants being offered in this offering, and we do not expect a market to develop.
In addition, we do not intend to apply to list the Pre-Funded Warrants or Series&nbsp;Warrants on any securities exchange or nationally
recognized trading system, including The Nasdaq Stock Market. Without an active market, the liquidity of the Pre-Funded Warrants or Series&nbsp;Warrants
will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of Pre-Funded Warrants or Series&nbsp;Warrants
purchased in this offering will have no rights as common stockholders until such holders exercise their Pre-Funded Warrants or Series&nbsp;Warrants
and acquire our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until holders of Pre-Funded
Warrants or Series&nbsp;Warrants acquire shares of our common stock upon exercise of the Pre-Funded Warrants or Series&nbsp;Warrants,
as applicable, holders of Pre-Funded Warrants or Series&nbsp;Warrants will have no rights with respect to the shares of our common stock
underlying such Pre-Funded Warrants or Series&nbsp;Warrants. Upon exercise of the Pre-Funded Warrants or Series&nbsp;Warrants, the holders
will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions of the Series&nbsp;Warrants
and Pre-Funded Warrants offered by this prospectus could discourage an acquisition of us by a third party.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the discussion
of the provisions of our Certificate of Incorporation, certain provisions of the Series&nbsp;Warrants and Pre-Funded Warrants offered
by this prospectus could make it more difficult or expensive for a third party to acquire us. Such Series&nbsp;Warrants and Pre-Funded
Warrants prohibit us from engaging in certain transactions constituting &ldquo;fundamental transactions&rdquo; unless, among other things,
the surviving entity assumes our obligations under the Series&nbsp;Warrants and Pre-Funded Warrants. Further, the Series&nbsp;Warrants
and Pre-Funded Warrants provide that, in the event of certain transactions constituting &ldquo;fundamental transactions,&rdquo; with
some exception, holders of such the Series&nbsp;Warrants and Pre-Funded Warrants will have the right, at their option, to require us
to repurchase such the Series&nbsp;Warrants and Pre-Funded Warrants at a price described in the Series&nbsp;Warrants and Pre-Funded Warrants.
These and other provisions of the Series&nbsp;Warrants and Pre-Funded Warrants offered by this prospectus could prevent or deter a third
party from acquiring us even where the acquisition could be beneficial to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>We may be required to repurchase certain
of our warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Certain
of our warrants sold privately that have registration rights, in the event of a &ldquo;Fundamental Transaction&rdquo; (as defined in
the related warrant agreement, which generally includes any merger with another entity, the sale, transfer or other disposition of all
or substantially all of our assets to another entity, or the acquisition by a person of more than 50% of our common stock), each warrant
holder will have the right at any time prior to the consummation of the Fundamental Transaction to require us to repurchase the warrant
for a purchase price in cash equal to the Black Scholes value (as calculated under the warrant agreement) of the then remaining unexercised
portion of such warrant on the date of such Fundamental Transaction, which may materially adversely affect our financial condition and/or
results of operations and may prevent or deter a third party from acquiring us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B><I>The Series&nbsp;Warrants may not have any value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #231f20">Each Series&nbsp;Warrant
will have an exercise price of $1.99 per share of common stock. The Series&nbsp;A Warrants will expire five years from the date of Warrant
Stockholder Approval and the Series&nbsp;B Warrants will expire one year from the date of Warrant Stockholder Approval. In the event
our common stock price does not exceed the exercise price of the Series&nbsp;Warrants during the period when the Series&nbsp;Warrants
are exercisable, the Series&nbsp;Warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231f20"><B><I>Stockholders may suffer substantial dilution
if certain provisions in the Series&nbsp;Warrants are utilized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the Series&nbsp;B Warrants are exercised by way of an alternative cashless exercise, assuming receipt of Warrant Stockholder Approval,
such exercising holder will receive three shares of Common Stock for each Series&nbsp;B Warrant they exercise, without any cash payment
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, and subject to certain exemptions, if we sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter
into an agreement to sell, or grant any right to reprice (excluding Exempt Issuances, as defined in the Placement Agency Agreement),
or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any shares of common
stock, at an effective price per share less than the exercise price of the Series&nbsp;A Warrants then in effect, the exercise price
of the Series&nbsp;A Warrants will be reduced to the lower of such price or the lowest volume weighted average price (VWAP) during the
five consecutive trading days immediately following such dilutive issuance or announcement thereof, and the number of shares issuable
upon exercise will be proportionately adjusted such that the aggregate exercise price will remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, if at any time the
Series&nbsp;A Warrants or Series&nbsp;B Warrants are outstanding and the Company receives notice from the Nasdaq Listing Qualifications
Department that the Company is failing to satisfy the $1.00 minimum bid requirement, then the Company has covenanted to take all necessary
steps to obtain the necessary consents and approvals to undertake a reverse stock split after such Trigger Date and shall, prior to the
effectiveness of any delisting notice issued by Nasdaq, effect such reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
any of the above provisions in the Series&nbsp;Warrants are utilized, our stockholders may suffer substantial dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will likely not receive any additional
funds upon the exercise of the Series&nbsp;B Warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #231f20">The Series&nbsp;B
Warrants may be exercised by way of an alternative cashless exercise, in which case the holder would not pay a cash purchase price upon
exercise, but instead would receive upon such exercise the number of shares equal to the number of Series&nbsp;B Warrants being exercised
multiplied by three. Accordingly, we will likely not receive any additional funds upon the exercise of the Series&nbsp;B Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The exercisability of the Series&nbsp;Warrants
is contingent upon us obtaining the Warrant Stockholder Approval. If we do not obtain such Warrant Stockholder Approval, the Series&nbsp;Warrants
may never become exercisable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series&nbsp;Warrants
are not immediately exercisable, as their exercisability is contingent upon us obtaining Warrant Stockholder Approval. The Series&nbsp;Warrants
will become exercisable upon Warrant Stockholder Approval and will expire on the five-year anniversary of such date with respect to the
Series&nbsp;A Warrants, and on the one-year anniversary of such date with respect to the Series&nbsp;B Warrants. While we intend to promptly
seek Warrant Stockholder Approval for these mechanisms, there is no guarantee that it will ever be obtained. In the event that we cannot
obtain Warrant Stockholder Approval, the&nbsp;Series&nbsp;Warrants&nbsp;may never become exercisable. If we are unable to obtain the
Warrant Stockholder Approval, the Series&nbsp;Warrants will have no value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to hold a
special meeting of shareholders (which may also be at the annual meeting of shareholders) at the earliest practicable date after the
date hereof, but in no event later than ninety days after the closing of the offering, in order to obtain Warrant Stockholder Approval.
There is no guarantee we will be able to hold a special meeting within this timeframe, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><B>Risks
Relating to Manufacturing, Development, and Industries:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>If the FDA implements
its plans to regulate LDTs, we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval
and costs associated with complying with post-market requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an LDT, our MDx Testing
Services are currently subject to enforcement discretion by the FDA. &nbsp;On April&nbsp;29, 2024, however, the FDA published a final
rule&nbsp;on LDTs, in which FDA outlines its plans to end enforcement discretion for many LDTs in five stages over a four-year period.
 &nbsp;In Phase 1 (effective May&nbsp;6, 2025), clinical laboratories running LDTs will be required to comply with medical device (adverse
event) reporting and correction/removal reporting requirements, as well as requirements for maintenance of complaint files under the
FDA&rsquo;s quality systems regulation (QSR). &nbsp;In Phase 2 (effective May&nbsp;6, 2026), clinical laboratories will be required to
comply with all other device requirements (e.g., registration/listing, labeling, investigational use), except for the remaining QSR requirements
and premarket review. &nbsp;In Phase 3 (effective May&nbsp;6, 2027), clinical laboratories will be required to comply with all remaining
QSR requirements. &nbsp;In Phase 4 (effective ~November&nbsp;6, 2027), clinical laboratories will be required to comply with premarket
review requirements for high-risk tests (<I>i.e.</I>, tests subject to the premarket approval (PMA) requirement). &nbsp;Finally, in Phase
5 (effective May&nbsp;6, 2028), clinical laboratories will be required to comply with premarket review requirements for moderate- and
low-risk tests (<I>i.e.</I>, tests subject to the&nbsp;<I>de novo</I>&nbsp;or 510(k)&nbsp;requirement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the final rule, several types of tests will be eligible for some degree of continued enforcement discretion, including LDTs approved
by NYSDOH. FDA notes, however, that it retains discretion to pursue enforcement action for violations of the FDCA at any time and intends
to do so when appropriate. FDA further explains that it may update any of the enforcement discretion policies set forth in the final
rule&nbsp;as circumstances warrant or if the circumstances that inform those policies change, consistent with FDA&rsquo;s good guidance
practices. Based on our current analysis of the FDA final rule, and assuming the final rule&nbsp;goes into effect without modification,
we believe that ADCL&rsquo;s current and future NYSDOH approved LDTs, which includes our under development PGx Testing Services, will
be exempt from FDA premarket review requirements but will remain subject to the requirements of Phases 1 through 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Congress
is also working on legislative language that would clarify FDA&rsquo;s authority with respect to LDTs &ndash; and if enacted, would potentially
supersede the final rule. &nbsp;In this regard, the &ldquo;Verifying Accurate Leading-edge IVCT Development Act,&rdquo; or VALID Act,
was most recently introduced in March&nbsp;2023. &nbsp;The bill proposes a risk-based approach that would subject many LDTs to FDA regulation
by creating a new&nbsp;<I>in vitro</I>&nbsp;clinical test, or IVCT, category of regulated products. As proposed, the bill would grandfather
many existing LDTs from the proposed premarket approval, quality systems, and labeling requirements, respectively, but would require
such tests to comply with other regulatory requirements (e.g., registration/listing, adverse event reporting). To market a high-risk
IVCT, reasonable assurance of analytical and clinical validity for the intended use would be needed to be established. Under VALID, a
precertification process would be established that would allow a laboratory to establish that the facilities, methods, and controls used
in the development of its IVCTs meet quality system requirements. If pre-certified, low-risk IVCTs developed by the laboratory and falling
within the scope of FDA&rsquo;s precertification order would not be subject to test-specific pre-market review. The new regulatory framework
would include quality control and post-market reporting requirements. The FDA would have the authority to withdraw approvals for IVCTs
for various reasons, including (for example) if there were a reasonable likelihood that the test would cause death or serious adverse
health consequences. However, we cannot predict if this (or any other bill) will be enacted in its current (or any other) form and cannot
quantify the effect of such proposals on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
the extent that FDA ultimately regulates certain LDTs, whether via final rule, final guidance, or as instructed by Congress, our LDTs
may be subject to certain additional regulatory requirements. Complying with the FDA&rsquo;s requirements may be expensive, time-consuming,
and subject us to significant or unanticipated delays. Insofar as we may be required to obtain premarket clearance or approval to perform
or continue performing an LDT, we cannot assure you that we will be able to obtain such authorization. Even if we obtain regulatory clearance
or approval where required, such authorization may not be for the intended uses that we believe are commercially attractive or are critical
to the commercial success of our tests. As a result, the application of the FDA&rsquo;s requirements to our tests could materially and
adversely affect our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Failure
to comply with applicable FDA regulatory requirements may trigger a range of enforcement actions by the FDA including warning letters,
civil monetary penalties, injunctions, criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown
of operations, and denial of or challenges to applications for clearance or approval, as well as significant adverse publicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that the net
proceeds from this offering will be approximately $10.8 million, assuming the sale of all
the securities offered under this prospectus, after deducting the Placement Agent fees and estimated offering expenses payable by us
and assuming no exercise of the Series&nbsp;Warrants. However, this is a best efforts offering with no minimum number of securities or
amount of proceeds as a condition to closing, and we may not sell all or any of these securities offered pursuant to this prospectus;
as a result, we may receive significantly less in net proceeds. We will only receive additional proceeds from the exercise of the Series&nbsp;A
Warrants issuable in connection with this offering if Warrant Stockholder Approval is obtained and such Series&nbsp;A Warrants are exercised
at their exercise price of $1.99 and the holders of such Series&nbsp;A Warrants pay the exercise price in cash upon such exercise. We
will only receive additional proceeds from the exercise of the Series&nbsp;B Warrants issuable in connection with this offering if Warrant
Stockholder Approval is obtained and such Series&nbsp;B Warrants are exercised at their exercise price of $1.99 and the holders of such
Series&nbsp;B Warrants pay the exercise price in cash upon such exercise. Such proceeds with respect to the Series&nbsp;A Warrants and
Series&nbsp;B Warrants could not exceed, in the aggregate, approximately $36.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing discussion
assumes no sale of Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net
proceeds from this offering for the further development of our Therapeutic DNA Production Services and MDx Testing Services, as well
as general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general
and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our
business, although we have no present commitments or agreements to make any such acquisitions or investments as of the date of this prospectus.
Pending these uses, we intend to invest the funds in short-term, investment grade, interest-bearing securities. It is possible that,
pending their use, we may invest the net proceeds in a way that does not yield a favorable, or any, return for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our expected use of net proceeds
from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus,
we cannot currently allocate specific percentages of the net proceeds that we may use for the purposes specified above, and we cannot
predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts
that we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending
on numerous factors, including our ability to obtain additional financing. We may find it necessary or advisable to use the net proceeds
for other purposes, and our management will have broad discretion in the application of the net proceeds, and investors will be relying
on our judgment regarding the application of the net proceeds from this offering. See &ldquo;Risk Factors&rdquo; for a discussion of
certain risks that may affect our intended use of the net proceeds from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>Market
Price of our Common Stock and Related Stockholder Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on The Nasdaq Stock Market under the symbol &ldquo;APDN.&rdquo; A description of the common stock that we are issuing in this offering
is set forth under the heading &ldquo;Description of Securities&rdquo; beginning on page&nbsp;19&nbsp;of this prospectus. We do not intend
to apply for the listing of the Pre-Funded Warrants or Series&nbsp;Warrants that are part of this offering on any national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The last reported sale price
for our common stock on May&nbsp;24, 2024 was $1.99 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of May&nbsp;24, 2024,
we had 269 record holders of our common stock, and no preferred stock issued and outstanding. The number of record holders was determined
from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various
security brokers, dealers, and registered clearing agencies. The transfer agent of our common stock and publicly traded warrants is Equiniti
Trust Company, LLC, located at 90 Park Avenue, New York, NY 10016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. We do not anticipate paying any cash dividends to stockholders in the foreseeable future.
In addition, any future determination to pay cash dividends will be at the discretion of the Board of Directors and will be dependent
upon our financial condition, results of operations, capital requirements, and such other factors as the Board of Directors deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>Capitalization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth our capitalization as of March&nbsp;31, 2024:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on a pro forma, as adjusted
    basis, after giving effect to the application of the net proceeds of this offering and after deducting the Placement Agent fees and
    estimated offering expenses payable by us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set forth
in the following table should be read in conjunction with and is qualified in its entirety by &ldquo;Use of Proceeds&rdquo; above, as
well as our &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial
statements and the notes to those financial statements incorporated by reference in this prospectus. See &ldquo;The Offering&rdquo; in
this prospectus for information relating to the expected number of shares of our common stock to be outstanding after this offering.
Our capitalization following the closing of this offering will be adjusted based on the actual public offering price and other terms
of this offering determined at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of March&nbsp;31, 2024</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pro Forma, As<BR>
Adjusted for<BR>
this Offering*</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">3,149,640</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">13,982,063</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Stockholders&rsquo; (Deficit) Equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March&nbsp;31, 2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Series&nbsp;A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares outstanding as of March&nbsp;31, 2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Series&nbsp;B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares outstanding as of March&nbsp;31, 2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Common stock, $0.001 par value per share; 200,000,000 shares authorized; 863,068 shares issued and outstanding as of March&nbsp;31, 2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">864</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10,095</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">308,206,796</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">319,029,988</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(308,255,808</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(308,255,808</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total Stockholders&rsquo; (Deficit) Equity</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(48,148</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">10,784,275</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">*Assumes a $12,000,000 capital
raise with net cash proceeds of $10,832,423 and the sale of 9,230,769 Units in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussion and table
above are based on the 863,068 shares of our common stock outstanding as of March&nbsp;31, 2024, and excludes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109,363 shares of common
    stock issuable upon exercise of options outstanding as of March&nbsp;31, 2024, with a weighted average exercise price of $184.60
    per share; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">945,867 shares of common
    stock issuable upon exercise of warrants outstanding as of March&nbsp;31, 2024, with a weighted average exercise price of $18.20
    per share; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,355 shares of common
    stock reserved for future grant or issuance as of March&nbsp;31, 2024, under our equity incentive plan; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_009"></A>Dilution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest in our common
stock and/or Pre-Funded Warrants in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the public offering price per share of our common stock underlying the Units and the as adjusted net tangible book value
per share of our common stock after this offering. Our net tangible book value as of March&nbsp;31, 2024 was approximately $2.5 million,
or $2.86 per share of our common stock. Net tangible book value per share is equal to our total tangible assets less our total liabilities,
divided by the number of shares of our outstanding common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to
the sale of Units in this offering at the public offering price of $1.30 per share, and after deducting the Placement Agent fee and
estimated offering expenses payable by us, and excluding the proceeds, if any, from the cash exercise of the Series&nbsp;Warrants
issued in this offering and assuming no Pre-Funded Warrants are issued in this offering, our as adjusted net tangible book value as
of March&nbsp;31, 2024 would have been $13,304,063, or $1.32 per share of common stock. This represents an immediate decrease in as
adjusted net tangible book value of $1.54 per share to our existing stockholders, and an immediate increase in as adjusted net
tangible book value of $0.02 per share to new investors purchasing securities in this offering at the public offering
price. The final public offering price was determined between us, the Co-Placement Agents and investors in the offering and may be
at a discount to the current market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table illustrates this dilution/accretion
on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%">Public offering price per share and accompanying Series&nbsp;Warrants</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1.30</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Historical net tangible book value per share as of March&nbsp;31, 2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.86</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Pro forma decrease in net tangible book value per share attributable to investors in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1.54</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">As adjusted net tangible book value per share after giving effect to this offering</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">1.32</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom">Accretion per share to investors participating in this offering</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt">(0.02</FONT></TD>
    <TD STYLE="vertical-align: bottom">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing discussion
and table do not take into account further dilution to investors in this offering that could occur upon the exercise of outstanding options
and warrants, including the Pre-Funded Warrants and Series&nbsp;Warrants offered in this offering, having a per share exercise price
less than the public offering price per share in this offering. The foregoing discussion and table also does not take into account any
 &ldquo;alternative cashless exercises&rdquo; of the Series&nbsp;B Warrants, pursuant to which the aggregate number of shares issuable
in such alternative cashless exercise would be equal to the number of Series&nbsp;B Warrants being exercised multiplied by three.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and table above are based on the 863,068 shares of
our common stock outstanding as of March&nbsp;31, 2024, and excludes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109,363 shares of common
    stock issuable upon exercise of options outstanding as of March&nbsp;31, 2024, with a weighted average exercise price of $184.60
    per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">945,867 shares of common
    stock issuable upon exercise of warrants outstanding as of March&nbsp;31, 2024, with a weighted average exercise price of $18.20
    per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">267,355 shares of common
    stock reserved for future grant or issuance as of March&nbsp;31, 2024, under our equity incentive plan; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussion and table
above assume no sale of Pre-Funded Warrants, which, if sold, would reduce the number of shares of common stock that we are offering on
a one<B>-</B>for-one basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that our outstanding
options or warrants are exercised, new options are issued under our equity incentive plan, or additional shares of our common stock are
issued in the future, there may be dilution to investors participating in this offering. In addition, we may choose to raise
additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our
current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance
of these securities could result in dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>Description
of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of our common stock, Pre-Funded Warrants and accompanying Series&nbsp;Warrants underlying the Units summarizes the material terms and
provisions of the securities that we may issue in connection with this offering. It may not contain all the information that is important
to you. For the complete terms of our common stock, please refer to our Certificate of Incorporation and our by-laws (&ldquo;By-Laws&rdquo;),
which are filed as exhibits to the registration statement which includes this prospectus. See &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation by Reference.&rdquo; The Delaware General Corporation Law (&ldquo;DGCL&rdquo;) may also affect the terms of
these securities. The summary below is qualified in its entirety by reference to our Certificate of Incorporation and By-Laws, each as
in effect at the time of any offering of securities under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of&nbsp;May&nbsp;24, 2024,
our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share, of which 984,728 shares were
issued and outstanding, and 10,000,000 shares of preferred stock, par value $0.001 per share, of which no shares were issued and outstanding.
In addition, as of May&nbsp;24, 2024, there were 109,363 shares of common stock issuable upon exercise of options outstanding, 825,067
shares of common stock issuable upon exercise of warrants outstanding, and 267,355 shares of common stock reserved for future grant or
issuance The authorized and unissued shares of common stock and preferred stock are available for issuance without further action by
our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each stockholder of our common
stock is entitled to one vote for each share issued and outstanding held on all matters to be voted upon by the stockholders. Our shares
of common stock have no preemptive, conversion, or redemption rights. The rights, preferences, and privileges of the holders of common
stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock. Upon the
sale of substantially all of our stock or assets or dissolution, liquidation or winding up, and after all liquidation preferences payable
to any series of preferred stock entitled thereto have been satisfied, our remaining assets shall be distributed to all holders of common
stock and any similarly situated stockholders who are not entitled to any liquidation preference or, if there be an insufficient amount
to pay all such stockholders, then ratably among such holders. All of our issued and outstanding shares of common stock are fully paid
and non-assessable. The holders of shares of our common stock will be entitled to such cash dividends as may be declared from time to
time by our Board of Directors from funds available therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
offered by this prospectus, when issued and paid for, will also be fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed
on The Nasdaq Capital Market under the symbol &ldquo;APDN.&rdquo; Equiniti Trust Company, LLC, located at 90 Park Avenue, New York, NY
10016, is the transfer agent and registrar for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
provides that our Board of Directors may, by resolution, designate classes of preferred stock in the future. The designated series of
preferred stock shall have such powers, designations, preferences and relative, participation or optional or other special rights and
qualifications, limitations or restrictions as shall be expressed in the resolution adopted by the Board of Directors. Once designated
by our Board of Directors, each series of preferred stock will have specific financial and other terms described in the documents that
govern the preferred stock, which include our Certificate of Incorporation and any certificates of designation that our Board of Directors
may adopt. Prior to the issuance of shares of each series of preferred stock, the Board of Directors is required by the DGCL and our
Certificate of Incorporation to adopt resolutions and file a certificate of designations with the Secretary of State of the State of
Delaware. The certificate of designations fixes for each class or series the designations, powers, preferences, rights, qualifications,
limitations and restrictions, including, but not limited to, some or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares constituting
    that series and the distinctive designation of that series, which number may be increased or decreased (but not below the number
    of shares then outstanding) from time to time by action of the Board of Directors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dividend rate and the
    manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative, and, if so, from
    which date;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether that series will
    have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether that series will
    have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion
    rate in such events as the Board of Directors may determine;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not the shares
    of that series will be redeemable, and, if so, the terms and conditions of such redemption;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether that series will
    have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not the shares
    of the series will have priority over or be on a parity with or be junior to the shares of any other series or class in any respect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rights of the shares
    of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative
    rights or priority, if any, of payment of shares of that series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other relative rights,
    preferences and limitations of that series.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our Board of Directors
has no intention at the present time of doing so, it could authorize the issuance of a series of preferred stock that could, depending
on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrant Stockholder Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Nasdaq listing rules,
the exercisability of the Series&nbsp;Warrants will not be effective until, and unless, we obtain the approval of our stockholders. While
we intend to promptly seek stockholder approval, and in no event later than 90 days following the closing of this offering, there is
no guarantee that the Warrant Stockholder Approval will ever be obtained. If we are unable to obtain the Warrant Stockholder Approval,
the Series&nbsp;Warrants will not be able to be exercised and will therefore have no value. In addition, we will incur substantial costs,
and management will devote substantial time and attention, in attempting to obtain the Warrant Stockholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Series&nbsp;Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following summary of certain terms and
provisions of the Series&nbsp;Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety
by, the provisions of the Series&nbsp;Warrants, the forms of which are filed as exhibits to the registration statement of which this
prospectus forms a part. Prospective investors should carefully review the terms and provisions of the forms of the Series&nbsp;Warrants
for complete descriptions of the terms and conditions of the Series&nbsp;Warrants.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series&nbsp;A Warrants
and Series&nbsp;B Warrants will become exercisable beginning on the date of the Warrant Stockholder Approval and at any time up to the
date that is five years from the Warrant Stockholder Approval date (with respect to the Series&nbsp;A Warrants) or one year from the
Warrant Stockholder Approval date (with respect to the Series&nbsp;B Warrants). If Warrant Stockholder Approval is obtained, the Series&nbsp;A
Warrants and Series&nbsp;B Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly
executed exercise notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon
such exercise. If a registration statement registering the issuance of the shares of common stock underlying the Series&nbsp;A Warrants
or Series&nbsp;B Warrants under the Securities Act is not effective, the holder may elect to exercise the Series&nbsp;A Warrants or Series&nbsp;B
Warrants through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock
determined according to the formula set forth in the warrant. No fractional shares of common stock will be issued in connection with
the exercise of Series&nbsp;A Warrants or Series&nbsp;B Warrants. In lieu of fractional shares, we will pay the holder an amount in cash
equal to the fractional amount multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder may also effect
an &ldquo;alternative cashless exercise&rdquo; at any time while the Series&nbsp;B Warrants are exercisable and outstanding. In such
event, the aggregate number of shares issuable in such alternative cashless exercise will be equal to the number of Series&nbsp;B Warrants
being exercised multiplied by three.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder will not have the
right to exercise any portion of the Series&nbsp;A Warrants or Series&nbsp;B Warrants if the holder (together with its affiliates) would
beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the Series&nbsp;A Warrants and Series&nbsp;B Warrants. However,
any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such
percentage shall &nbsp;not be effective until 61 days following notice from the holder to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price per whole
share of common stock purchasable upon exercise of the Series&nbsp;A Warrants is $1.99, and the exercise price per whole share of common
stock purchasable upon exercise of the Series&nbsp;B Warrants is $1.99. The exercise price of the Series&nbsp;A Warrants and Series&nbsp;B
Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations,
reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other
property to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, and subject
to certain exemptions, if we sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement
to sell, or grant any right to reprice (excluding Exempt Issuances, as defined in the Placement Agency Agreement), or otherwise dispose
of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any shares of common stock, at an effective
price per share less than the exercise price of the Series&nbsp;A Warrants then in effect, the exercise price of the Series&nbsp;A Warrants
will be reduced to the lower of such price or the lowest volume weighted average price (VWAP) during the five consecutive trading days
immediately following such dilutive issuance or announcement thereof, and the number of shares issuable upon exercise will be proportionately
adjusted such that the aggregate exercise price will remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time on or after
the date of issuance there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving
our common stock and the lowest daily volume weighted average price during the period commencing five consecutive trading days immediately
preceding and the five consecutive trading days commencing on the date of such event is less than the exercise price of the Series&nbsp;A
Warrants or Series&nbsp;B Warrants then in effect, then the exercise price of the Series&nbsp;A Warrants and Series&nbsp;B Warrants will
be reduced to the lowest daily volume weighted average price during such period and the number of shares issuable upon exercise will
be proportionately adjusted such that the aggregate price will remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable laws,
the Series&nbsp;A Warrants and Series&nbsp;B Warrants may be offered for sale, sold, transferred or assigned without our consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of certain fundamental
transactions affecting the Company, a holder of Series&nbsp;Warrants, upon exercise of such Series&nbsp;Warrants after such fundamental
transaction, will have the right to receive, in lieu of shares of the Company&rsquo;s common stock, the same amount and kind of securities,
cash or property that such holder would have been entitled to receive upon the occurrence of the fundamental transaction, had the Series&nbsp;Warrants
been exercised immediately prior to such fundamental transaction. In lieu of such consideration, a holder of Series&nbsp;Warrants may
instead elect to receive a cash payment based upon the Black-Scholes value of their Series&nbsp;Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in the Series&nbsp;A Warrants or Series&nbsp;B Warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock,
the holder of Series&nbsp;A Warrants or Series&nbsp;B Warrants does not have the rights or privileges of a holder of our common stock,
including any voting rights, until the holder exercises the Series&nbsp;A Warrant or Series&nbsp;B Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the Series&nbsp;A
Warrants or Series&nbsp;B Warrants are outstanding and the Company receives notice from the Nasdaq Listing Qualifications Department
that the Company is failing to satisfy the $1.00 minimum bid requirement, then the Company has covenanted to take all necessary steps
to obtain the necessary consents and approvals to undertake a reverse stock split after such Trigger Date and shall, prior to the effectiveness
of any delisting notice issued by Nasdaq, effect such reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series&nbsp;A Warrants
and the Series&nbsp;B Warrants are governed by New York law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to list
the Series&nbsp;Warrants on any securities exchange or nationally recognized trading system. Except as otherwise provided in the Series&nbsp;Warrants
or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holders of the Series&nbsp;Warrants do not have the
rights or privileges of holders of our common stock, including any voting rights, until they exercise their Series&nbsp;Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have agreed
to hold a special meeting of shareholders (which may also be at the annual meeting of shareholders) at the earliest practicable date
after the date hereof, but in no event later than ninety days after the closing of the offering, in order to obtain Warrant Stockholder
Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pre-Funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following summary
of certain terms and provisions of Pre-Funded Warrants that are being offered hereby is not complete and is subject to, and qualified
in its entirety by, the provisions of the Pre-Funded Warrant, the form of which is filed as an exhibit to the registration statement
of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded
Warrant for a complete description of the terms and conditions of the Pre-Funded Warrants.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Pre-Funded Warrant offered
hereby will have an initial exercise price per share equal to $0.0001. The Pre-Funded Warrants will be immediately exercisable and may
be exercised at any time until the Pre-Funded Warrants are exercised in full. The exercise price and number of shares of common stock
issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar
events affecting our common stock and the exercise price. The Pre-Funded Warrants will be issued separately from the accompanying Series&nbsp;Warrants
and may be transferred separately immediately thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-Funded Warrants will
be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by
payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise
as discussed below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that
the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise,
except that upon at least 61 days&rsquo; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding
stock after exercising the holder&rsquo;s Pre-Funded Warrants up to 9.99 % of the number of shares of our common stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants.
Purchasers of Pre-Funded Warrants in this offering may also elect prior to the issuance of the Pre-Funded Warrants to have the initial
exercise limitation set at 9.99% of our outstanding common stock. No fractional shares of common stock will be issued in connection with
the exercise of a Pre-Funded Warrant. In lieu of fractional shares, we will round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At any time, in lieu of making
the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may
elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according
to a formula set forth in the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable laws,
a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the
appropriate instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to list
the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. Except as otherwise provided in the Pre-Funded
Warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holders of the Pre-Funded Warrants do not have
the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Possible Anti-Takeover Effects of Delaware Law and our Certificate
of Incorporation and By-Laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
contains provisions that could make it more difficult to acquire control of our company by means of a tender offer, open market purchases,
a proxy contest or otherwise. A description of these provisions is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Anti-Takeover Effects of Delaware Law</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies incorporated in
Delaware are subject to the provisions of Section&nbsp;203 of the DGCL, or Section&nbsp;203, unless the corporation has &ldquo;opted
out&rdquo; of these provisions with an express provision in its original certificate of incorporation or an express provision in its
certificate of incorporation or by-laws resulting from a stockholders&rsquo; amendment approved by at least a majority of the outstanding
voting shares. We have opted out of Section&nbsp;203 with an express provision in our Certificate of Incorporation. Therefore, the anti-takeover
effects of Section&nbsp;203 do not apply to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, Section&nbsp;203
prohibits a publicly-held Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo;
for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is
approved in a prescribed manner. A &ldquo;business combination&rdquo; includes, among other things, a merger, asset or stock sale or
other transaction resulting in a financial benefit to the interested stockholder. An &ldquo;interested stockholder&rdquo; is a person
who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder
status, 15% or more of the corporation&rsquo;s voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Section&nbsp;203, a
business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
before the stockholder became interested, the Board of Directors approved either the business combination or the transaction which resulted
in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming
an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors
and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business
combination was approved by the Board of Directors of the corporation and authorized at an annual or special meeting of the stockholders
by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Election and Removal of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors will be elected
by a plurality of the voting power of the shares present in person or represented by proxy at the stockholders meeting and entitled to
vote on the election of directors. Our Certificate of Incorporation does not provide for a classified Board of Directors or for cumulative
voting in the election of directors. Under Article&nbsp;VIII of the Certificate of Incorporation and Section&nbsp;3.13 of the By-Laws,
directors may be removed by the stockholders of the Company only for cause, and in such case only by the affirmative vote of the holders
of at least a majority of the voting power of the issued and outstanding shares of capital stock of the Company then entitled to vote
in the election of directors. On December&nbsp;21, 2015, the Court of Chancery of the State of Delaware invalidated as a matter of law
certain provisions of the certificate of incorporation and bylaws of VAALCO Energy,&nbsp;Inc. (&ldquo;VAALCO&rdquo;), a Delaware corporation,
that permitted the removal of VAALCO&rsquo;s directors by its stockholders only for cause. In&nbsp;<I>In re VAALCO Energy,&nbsp;Inc.
Stockholder Litigation,&nbsp;</I>Consol. C.A. No.&nbsp;11775-VCL (Del. Ch. Dec.&nbsp;21, 2015), the Court ruled from the bench to hold
that, in the absence of a classified Board of Directors or cumulative voting, VAALCO&rsquo;s &ldquo;only for-cause&rdquo; director removal
provisions conflict with Section&nbsp;141(k)&nbsp;of the DGCL and are therefore invalid. Because the Company&rsquo;s Certificate of Incorporation
and By-Laws contain similar &ldquo;only for-cause&rdquo; director removal provisions and the Company does not have a classified Board
of Directors or cumulative voting, the Company will not attempt to enforce the foregoing &ldquo;only for-cause&rdquo; director removal
provision in light of the recent&nbsp;<I>VAALCO</I>&nbsp;decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Size of Board and Vacancies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The authorized number of
directors may be determined by the Board of Directors, provided the board shall consist of at least one (1)&nbsp;member. No decrease
in the number of directors constituting the board shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vacancies occurring on our
Board of Directors for any reason and newly created directorships resulting from an increase in the authorized number of directors may
be filled only by a vote of a majority of the remaining members of the Board of Directors, although less than a quorum, or by a sole
remaining director, at any meeting of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Amendment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Certificate of Incorporation
may be amended in the manner prescribed by the DGCL. The Board of Directors is authorized to adopt, amend, alter or repeal the By-Laws
by the affirmative vote of at least a majority of the Board of Directors then in office. No amendment to the Certificate of Incorporation
or the By-Laws may adversely affect any indemnification right or protection of any director, officer, employee or other agent existing
at the time of such amendment, repeal or adoption of an inconsistent provision for or in respect of any act, omission or other matter
occurring, or any action or proceeding accruing or arising prior to such amendment, repeal or adoption of an inconsistent provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Authorized but Unissued Shares of Common Stock
and of Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the availability
of the &ldquo;Blank Check&rdquo; preferred stock under our Certificate of Incorporation provides us with flexibility in addressing corporate
issues that may arise. The Board of Directors has the power, subject to applicable law, to issue series of preferred stock that could,
depending on the terms of the series, impede the completion of a merger, tender offer or other takeover attempt that some, or a majority,
of the stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over
the then prevailing market price of the stock. Our Board of Directors may issue preferred stock with voting rights or conversion rights
that, if exercised, could adversely affect the voting power of the holders of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The authorized shares of
preferred stock, as well as shares of common stock, will be available for issuance without further action by our stockholders, unless
action is required by applicable law or the rules&nbsp;of any stock exchange on which our securities may be listed. Having these authorized
shares available for issuance allows us to issue shares without the expense and delay of a special stockholders&rsquo; meeting. We may
use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions
and as employee compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult
or discourage an attempt to obtain control of our company by means of a proxy contest, tender offer, merger or otherwise. The above provisions
may deter a hostile takeover or delay a change in control or management of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Advance Notice Procedure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our By-Laws provide an advance
notice procedure for stockholders to nominate director candidates for election or to bring business before an annual meeting of stockholders.
Only persons nominated by, or at the direction of, our Board of Directors or by a stockholder of record who has given proper and timely
notice to our secretary prior to the meeting at which such stockholder is entitled to vote and appears, will be eligible for election
as a director. In addition, any proposed business other than the nomination of persons for election to our Board of Directors must constitute
a proper matter for stockholder action pursuant to a proper notice of meeting delivered to us. For notice to be timely, it must generally
be delivered to our secretary not less than 90 nor more than 120 calendar days prior to the first anniversary of the previous year&rsquo;s
annual meeting (or if the date of the annual meeting is more than 30 calendar days before or more than 60 calendar days after the anniversary
date of the previous year&rsquo;s annual meeting, not earlier than the 120th calendar day prior to such meeting and not later than either
the 90th calendar day prior to such meeting or the 10th calendar day after public disclosure of the date of such meeting is first made
by us). These advance notice provisions may have the effect of precluding the conduct of certain business at a meeting if the proper
procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own
slate of directors or otherwise attempt to obtain control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Special Meetings of Stockholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our By-Laws provide that special meetings of
stockholders may be called only by the Chairman of the Board, the Chief Executive Officer, or the Board of Directors pursuant to a resolution
adopted by a majority of the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_011"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to a placement agency
agreement, dated as of May&nbsp;28, 2024, we have engaged Craig-Hallum and Laidlaw, or the Co-Placement Agents, to act as our exclusive
placement agents to solicit offers to purchase the Units offered by this prospectus on a best efforts basis. The placement agency agreement
does not give rise to any commitment by the Co-Placement Agents to purchase any of our securities, and the Co-Placement Agents will have
no authority to bind us by virtue of the placement agency agreement. The Co-Placement Agents are not purchasing or selling any such securities,
nor is it required to arrange for the purchase and sale of any specific number or dollar amount of such securities, other than to use
their &ldquo; best efforts&rdquo; to arrange for the sale of such securities by us. Therefore, we may not sell all, or any, of the Units
being offered. The terms of this offering were subject to market conditions and negotiations between us, the Co-Placement Agents and
prospective investors. This is a best efforts offering and there is no minimum number of securities or minimum aggregate amount of proceeds
that is a condition to the closing of this offering. The Co-Placement Agents may retain sub-agents and selected dealers in connection
with this offering. <FONT STYLE="background-color: white">This offering will terminate on June&nbsp;30, 2024, unless we decide to terminate
the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased
in this offering. The public offering price per Unit will be fixed for the duration of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delivery of the securities
offered hereby is expected to occur on or about May&nbsp;29, 2024, subject to satisfaction of certain customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to pay the
Co-Placement Agents an aggregate fee equal to 7.0% of the gross proceeds received in the offering <FONT STYLE="background-color: white">and
will issue to the Co-Placement Agents, or their respective designees, Placement Agent Warrants to purchase up to 461,538 shares of common
stock (which equals 5.0% of the number of Units being offered) on substantially the same terms as the </FONT>Series&nbsp;<FONT STYLE="background-color: white">Warrants,
except that the Placement Agent Warrants will have an expiration date of five years from the commencement of sales in this offering</FONT>.
The Placement Agent Warrants and the underlying shares of common stock are being registered on this prospectus. In addition, we have
agreed to reimburse the Co-Placement Agents for their legal fees, costs and expenses in connection with this offering in an amount up
to $110,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate the total expenses
of this offering paid or payable by us, exclusive of the Co-Placement Agents&rsquo; cash fees and expenses, will be approximately $217,577.
After deducting the fees due to the Co-Placement Agents and our estimated expenses in connection with this offering, we expect the net
proceeds from this offering will be approximately $10,832,400&nbsp;based on a public offering price of $1.30 per Unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows
the per share and total cash fees we will pay to the Co-Placement Agents in connection with the sale of the securities pursuant to this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per<BR>
Share and <BR>
Series&nbsp;Warrants</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Pre-Funded<BR>
Warrant and <BR>
Series&nbsp;Warrants</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; width: 61%"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1.30</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1.2999</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">12,000,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Placement Agent fees</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">$</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.091</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">$</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.09099</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">$</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">840,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1.209</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1.20891</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">11,160,000</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify
the Co-Placement Agents against certain liabilities, including liabilities under the Securities Act and liabilities arising from breaches
of representations, warranties and covenants contained in our placement agency agreement with the Co-Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Determination of Public Offering Price and Warrant Exercise Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is currently
traded on The Nasdaq Capital Market under the symbol &ldquo;APDN.&rdquo; On May&nbsp;24, 2024, the closing price of our common stock
was $1.99 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The final public offering
price of the Units and the exercise price of the Series&nbsp;Warrants that we are offering, was negotiated between us, the Co-Placement
Agents and the investors in this offering. We believe that the market price of our common stock at the date of this prospectus is not
the appropriate public offering price for the shares of our common stock because the market price is affected by a number of factors.
The principal factors considered by us and the Co-Placement Agents in determining the final public offering price of the Units we are
offering, as well as the exercise price of the Series&nbsp;Warrants that we are offering, included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recent trading history
    of our common stock on The Nasdaq Capital Market, including market prices and trading volume of our common stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the current market price
    of our common stock on The Nasdaq Capital Market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recent market prices
    of, and demand for, publicly traded common stock of generally comparable companies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information set forth
    or incorporated by reference in this prospectus and otherwise available to the Co-Placement Agents;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our past and present financial
    performance and an assessment of our management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our prospects for future
    earnings and the present state of our products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the current status of competitive
    products and product developments by our competitors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history and prospects,
    and the history and prospects of the industry in which we compete;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the general condition of
    the securities markets at the time of this offering; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other factors deemed relevant
    by the Co-Placement Agents and us, including a to be negotiated discount to the trading price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tail Fees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have also agreed to pay Craig-Hallum a cash fee equal to 7.0% of the total gross proceeds received by us from any investor who was contacted
by Craig-Hallum, if such investor provides us with capital in any offering or other financing or capital raising transaction during the
term of the engagement with Craig-Hallum or within six&nbsp;months following the expiration or termination of the engagement with Craig-Hallum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our officers and
directors have agreed to be subject to a lock-up period of 90 days following the date of closing of the offering pursuant to this prospectus.
This means that, during the applicable lock-up period, such persons may not offer for sale, contract to sell, sell, distribute, grant
any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any of our shares of common
stock or any securities convertible into, or exercisable or exchangeable for, shares of common stock, subject to customary exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to be subject
to a lock-up period of one year following the date of closing of the offering pursuant to this prospectus. This means that, during the
applicable lock-up period, we may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase,
pledge, hypothecate or otherwise dispose of, directly or indirectly, any of our shares of common stock or any securities convertible
into, or exercisable or exchangeable for, shares of common stock, subject to customary exceptions. However, this lock-up period shall
terminate upon the earlier of 90 days after (i)&nbsp;the closing of this offering if the Warrant Stockholder Approval is obtained prior
to 90 days after the closing of this offering and (ii)&nbsp;the date that Warrant Stockholder Approval is obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have also agreed, subject to certain exceptions,
to a restriction on the issuance of any variable priced securities for 180 days after the closing of this offering, although we will
be permitted to issue stock options or stock awards to directors, officers and employees under our existing plans. Craig-Hallum may waive
the terms of these lock-up agreements in its sole discretion and without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Right of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">We
have granted Craig-Hallum a right of first refusal, for a period commencing after the closing of this offering and ending on the date
on which the Series&nbsp;B Warrants are no longer outstanding, to act as sole bookrunner, exclusive placement agent or exclusive sales
agent in connection with any financing in which we decide to raise funds by means of a solicitation of any of the Series&nbsp;B Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Co-Placement
Agents may provide in the future various advisory, investment and commercial banking and other services to us in the ordinary course
of business, for which they may receive customary fees and commissions. However, except as disclosed in this prospectus, we have no present
arrangements with the Co-Placement Agents for any further services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulation M Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Co-Placement Agents may
be deemed to be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act, and any commissions received by it
and any profit realized on the sale of our securities offered hereby by it while acting as principal might be deemed to be underwriting
discounts or commissions under the Securities Act. The Co-Placement Agents will be required to comply with the requirements of the Securities
Act and the Exchange Act, including, without limitation, Rule&nbsp;10b-5 and Regulation M under the Exchange Act. These rules&nbsp;and
regulations may limit the timing of purchases and sales of our securities by the Co-Placement Agents. Under these rules&nbsp;and regulations,
the Co-Placement Agents may not (i)&nbsp;engage in any stabilization activity in connection with our securities; and (ii)&nbsp;bid for
or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the
Exchange Act, until they have completed their participation in the distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus in electronic
format may be made available on websites or through other online services maintained by the Co-Placement Agents, or by their affiliates.
Other than this prospectus in electronic format, the information on the Co-Placement Agents&rsquo; websites and any information contained
in any other website maintained by the Co-Placement Agents is not part of this prospectus or the registration statement of which this
prospectus forms a part, has not been approved and/or endorsed by us or the Co-Placement Agents in their capacity as placement agent,
and should not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_012"></A>Experts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marcum LLP, independent registered
public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form&nbsp;10-K for the years
ended September&nbsp;30, 2023 and 2022, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere
in this registration statement. Marcum LLP&rsquo;s report includes an explanatory paragraph relating to our ability to continue as a
going concern. Our consolidated financial statements are incorporated by reference in reliance on Marcum LLP&rsquo;s report, given on
their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_013"></A>Legal
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain legal matters relating
to the issuance of the securities offered by this prospectus will be passed upon for us by McDermott Will&nbsp;&amp; Emery LLP, New York,
New York. Certain legal matters in connection with this offering will be passed upon for the Co-Placement Agents by Ellenoff Grossman&nbsp;&amp;
Schole LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_014"></A>Where
you can find more information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the securities offered by this prospectus. This prospectus,
which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement,
as permitted by the rules&nbsp;and regulations of the SEC. For further information with respect to us and our securities, we refer you
to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus
concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed
as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this
prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also maintains
an Internet website that contains the registration statement of which this prospectus forms a part, as well as the exhibits thereto.
These documents, along with future reports, proxy statements and other information about us, are available at the SEC&rsquo;s website,
<U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act, and, in accordance with this law, file periodic reports and other information with the
SEC. These periodic reports and other information are available at the SEC&rsquo;s website, <U>www.sec.gov</U>. We also maintain a website
at <U>http://www.adnas.com</U>. You may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus, and the inclusion of our
website address in this prospectus is an inactive textual reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_015"></A>MATERIAL
CHANGES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_016"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
SEC allows us to &ldquo;incorporate by reference&rdquo; into this prospectus the information in documents we file with it, which means
that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered
to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information.
Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
or superseded for purposes of this prospectus to the extent that a statement contained in or omitted from this prospectus or any accompanying
prospectus supplement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein,
modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
incorporate by reference the documents listed below and any future documents that we file with the SEC (excluding any portion of such
documents that are furnished and not filed with the SEC) under Sections 13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act (1)&nbsp;on
and after the date of the initial filing of the registration statement of which this prospectus is a part prior to the effectiveness
of the registration statement, (2)&nbsp;prior to the effectiveness of the registration statement of which this prospectus is a part,
and (3)&nbsp;after the date of effectiveness of this prospectus until the offering of the underlying securities is terminated; provided,
however, we are not incorporating by reference any information furnished (but not filed) under Item 2.02 or Item 7.01 of any Current
Report on&nbsp;Form&nbsp;8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on Form&nbsp;10-K&nbsp;for the fiscal year September&nbsp;30, 2023 filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000141057823002615/apdn-20230930x10k.htm" STYLE="-sec-extract: exhibit">December&nbsp;7,
    2023</A></FONT>, as amended on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924007279/tm244099d1_10ka.htm" STYLE="-sec-extract: exhibit">January&nbsp;26,
    2024</A>.</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Reports on Form&nbsp;10-Q for the three month periods ended December&nbsp;31, 2023 and March&nbsp;31, 2024 filed with the
    SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000141057824000021/apdn-20231231x10q.htm" STYLE="-sec-extract: exhibit">February&nbsp;8,
    2024</A></FONT> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000141057824000733/apdn-20240331x10q.htm" STYLE="-sec-extract: exhibit">May&nbsp;10,
    2024</A>, respectively.</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form&nbsp;8-K&nbsp;filed with the SEC on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465923115320/tm2329968d1_8k.htm" STYLE="-sec-extract: exhibit">November&nbsp;7,
    2023</A></FONT>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465923123962/tm2332138d1_8k.htm" STYLE="-sec-extract: exhibit">December&nbsp;6,
    2023</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924001819/tm242253d1_8k.htm" STYLE="-sec-extract: exhibit">January&nbsp;5,
    2024</A>,&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924008438/tm244443d1_8k.htm" STYLE="-sec-extract: exhibit">January&nbsp;31,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924008937/tm244700d1_8k.htm" STYLE="-sec-extract: exhibit">February&nbsp;1,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924047787/tm2411831d1_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;16,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924049449/tm2412291d1_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;19,
    2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924050056/tm2412346d1_8k.htm" STYLE="-sec-extract: exhibit">April&nbsp;22,
    2024</A> (excluding Item 7.01), as amended on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924050524/tm2412515d1_8ka.htm" STYLE="-sec-extract: exhibit">April&nbsp;23,
    2024</A> (excluding Item 7.01) and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/744452/000110465924062618/tm2414775d1_8k.htm" STYLE="-sec-extract: exhibit">May&nbsp;16,
    2024</A>.</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/744452/000110465924034530/tm247721-2_def14a.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Definitive Proxy Statement on Schedule 14A, filed with the SEC on&nbsp;March&nbsp;14, 2024</FONT>.</A></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our capital stock contained in our registration statement on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/744452/000157104914006275/t1402186_8a12b.htm" STYLE="-sec-extract: exhibit">Form&nbsp;8-A
    (File No.&nbsp;001-36745) filed with the Commission on November&nbsp;13, 2014</A></FONT>, pursuant to Section&nbsp;12(b)&nbsp;of
    the Exchange Act, including any amendment or report filed for the purpose of updating such description.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Upon
written or oral request, we will provide without charge to each person, including any beneficial owner, to whom a copy of the prospectus
is delivered a copy of the documents incorporated by reference in this prospectus (other than exhibits to such documents unless such
exhibits are specifically incorporated by reference in this prospectus). You may request a copy of these filings, at no cost, by writing
or telephoning us at the following address: Applied DNA Sciences,&nbsp;Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, c/o
Investor Relations, telephone: 631-240-8800.&nbsp;You&nbsp;may also access these documents on our website at&nbsp;<I><U>www.adnas.com</U></I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information on our website,
including subsections, pages, or other subdivisions of our website, or any website linked to by content on our website, is not part of
this prospectus and you should not rely on that information unless that information is also in this prospectus or incorporated by reference
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to&nbsp; 9,230,769 Units, Each Unit Consisting
of One Share of Common Stock or One</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pre-Funded Warrant to Purchase One Share of
Common Stock, One Series&nbsp;A Warrant to Purchase One Share of Common Stock and One Series&nbsp;B Warrant to Purchase One Share of
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Placement Agent Warrants to Purchase Up to
461,538 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 28,153,845 Shares of Common Stock Underlying
the Pre-Funded Warrants, Series&nbsp;A Warrants, Series&nbsp;B Warrants and Placement Agent Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2412319d10_424b4img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Craig-Hallum</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Laidlaw&nbsp;&amp;
    Company (UK) Ltd.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May&nbsp;28, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2412319d10_424b4img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2412319d10_424b4img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !K HH# 2(  A$! Q$!_\0
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MQF^'?P(\-W?C+XF>(;?PUX<M,23ZA-,=L:/+'$/,0GY5+R#!7( VD]<5YC\
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M*;R]+T^\MYDANR)A&9 ER(G$)AP48*=SY"G@@\NKV7?Y;OY(#]K/&WQ)\"^
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M!(ZXR<D^G-5"I&:O%Z7MV;?:WS0-I=5]Z_S+*,64$XSE@<=/E8KW^E,9WW,
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M36\JPR<_:<\L#MXR,9/.:^]OV#O^"Q7[)O\ P4$U6[T'X.ZK?6?B-$ N+*]
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M31"%/*4X"AR"9 1G  /JGPW_ &S?VB/A>UFFC?$_Q-)ID,B1S:;/JMWYHCC
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M(QCCJ?#WQ!\*^,;=CX7U_3O$>UPS?V7?V]ZD((_Y:1VSRJG7 W,HW<CG /\
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MIV/VVRF+3QW$:7"XFFO8"Y+RE6S\H#%0@9:G_P""HG_!M?X__8=\#O\ 'O\
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M^/?B5X>M;J/P!;6^H1-(YS:D375NZQ,C?(Q'0%L$;E![BO%?^#EJ56_X*O\
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MYB3\U?$'Q8D:Y_X*,Z;;ZC,)'_X35%B$JDA5&J2@; Q)4#=E,Y)P!V-?V?\
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M\&?[(_[-'C[_ (+(?M'>-_%OQA^.,'@OPB==FU:XD\2ZU#% 8%#$1P1W]]
M"F(T";)=I;;A3BO[)O\ @ZZ\&^*O$7['$=]X?@GOK&!8GOI8?F CA=A,I$7R
M'"2REE*XPF,!037\/O\ P31_8K^.W[8VI:QX4_9\^)5QX(U[0+*YDO8UU :/
M)?3"9/.B+,T1EV1,WRNS( 22"P7 !_13\</^#9O]CG3/A1K?B/X7_M7>")?&
M.B:/<W,&FP^(M&EN+N_M+228+#LU9I SRQJD06-W9F"C.17YY_\ !$[]OKXQ
M?L&_MR:9^RIXM\9:GXJ^'.L^)+OPUYEMJYET^&,W/G1RJK&=$60NQ#(0A+_+
MC<*]7U+_ (($_P#!4[P_IUUKNO?&K5])L--1[BXN9/%8BMFM($\R>6=Q=G?'
MY:DR8V_(&&0QW#L?^";7_!%SPK#^UOX2\9?$[]HGPWXCU[PQJDE]JNCVVJVU
M[J<VH"5"JJR2-*SIO5"-R[05.X^4Q8 ^IO\ @[:_:(^*+ZQ\*_A[HESX@TCX
M:>(;:W622T:XBL+C3[C[&TK%X2D4YD$I0 2$R!@-QW<<]_P2Q_X)'_\ !+/]
MIO\ 9[\+ZUX\^*_AEOB9KFF2K?6VMZYHUK<QW4D:I*@2YU!I7=))58DQJR[%
MY.,#^HS_ (*6_P#!*?X,_M__  <\/?#_ %^\MM*\8^'= DM/#E\;RW::686D
M(MP&<2$'?"C+\K/\K\\!J_A5_:N_X(6_\%!_V 8]7\;?"3Q-KM_X.\+,VJ?;
M],U<PQV5M&[2F,B"XB)PL8'RJH?.".%H _N%_P""4W_!)CP)_P $X=1\;WOP
MQ\56FO>&O%C^;'#8W$<]O'9[[R2)EGBFGAD;R[IF"DL-QXP'&[]2?VA_AS;?
M&;X.>/?A6=KCQMX=U+2(E=1(#YP)B;&8QAG=L;G^8+\@ZBOX]O\ @V>_X*O?
M&CX[>-_%'[,_QRU2^U[5O#L6GV.F37%Q+-<1.KWBW"R2R,S8BDB54+-F1 S<
M]:_MP^S^9,L@93) %(2,1J41,_)\BY>5L')&!\N-HQS,X\\7&]K]59_F!_B@
M_P#!1S]CCX@_L<_M-?%/P!XQT'5M.L3XRUN30M2OM,NK;3+JRN-3NI"MO-(J
M($A4H6(ED6-)(]Y!PS?4_P#P3M_X*T?'O]C;2I/AIX7UZ_M?!TM]YD]G'J,D
M5JTLN1YFSRV48&[&\D8?C/&/])C_ (*D_P#!(_X(_P#!13X<ZO#K&@V=C\18
M[>Y_L/7%A@MYEN[B%4E-W<)$7D_>PPD/O7!:0DY(V_YI/_!0+_@CK^U5^PAX
MQU:SU?PK>ZYX/M"]W:>)=,_TN-[8%I(HB\#EC($*K\RG<H)!4KBO4RO%T\)4
M4*D9.,K/FBX)+DZ2<W&.M]-5>S[HRKX=8JC4P[2<*D>62W?2S2ZVMV9_3W\#
M/V]OVUOVF=%MO$/PK\7Q^(E4Q2QZ-;ZD\]S%*XX5E@Y*KG<!M&[:><=?IR?X
MA_\ !5R.2/[;HOBFPD= \!MX-4=9$*$C;MM]K[\9P3D G)QFOX0OV4OV[OCU
M^QIXD&L_"_Q/<6"+<(VH:+J<]T4BGBS$R?9I9%48Z2#RV.>0R#(K^GC]GS_@
MZL^(<UG8Z#\6O"6E7MPD,<5OJL=A!YD9143S6D&[:$V'(X7#9;MC]$P_$&7^
MRI4HTVG\*4IQNW)Q2]V#EU:332\D?FN><,RE4G+V%]]5&3N^S]U]M/S1^FL'
MQ-_X*HF.X_XDOC17)),QM=46,L"%VF3R64 M@G&!P64=<3CXF?\ !5=2!_8'
MBXL"/F>#5SG)!R#]FS@!@ ><=S6-X/\ ^#@?5O&EE9R>'O#VAZC]JE!\E+>W
M,A5BP)9-^Z3G!! "'/(ZD>V3_P#!83XZQPV5S;_"*:\MKA6/FV^B)*?F=AN(
M5>< J=NTY&U<Y8U]!3G*I?\ V;#OE=ES02UZ6NENUK?3N[7/SO%8>>#JRI?5
M:U-Q;4G:*4FM$TW;TNGH]CR__A9/_!5;YBFB>+P>< 0ZL,,0#G=]FZ9QWQ^5
M4KGXA?\ !5BZ259='\17MNB%8],NK#42SQD%GC+26Y9_,. #AL':RYP37J#_
M /!8WX]HP+?"1T4\@/HBHP7.&W+Y9PPQR,9Z<#/,8_X+"_'-<RO\*5WC!7.B
M[6PH#  !>#GGJ22<\YKV<++&WBO[-P248N*YZ44I7U^*$9)+I=.ZO==&>9"O
MC?K%I3S&-."VA6<4H73G:TE=V3MUV/SS^.7[)_[5_P"T7I\L7Q%^!5T][<C9
M<7\FB7C,PWR-F/%E'APTA;)] Q.?F/XU?&G_ ((%?M9SQW7B#P)\.M4E5'NI
MY;&TT6^=UCB57B1F17.2/,094?. !DY!_J@3_@L7\=II3CX4,\>U<@:,VP,2
M<A@$"@XP>2!T'0U<3_@L9\?((ITMOA$I:3RAM;11@@;G)[@<\$ELX^7O7+C<
M#F-934:6'@ZK:C&$FHT^;W;JR=^5M23DNEMM3[G)L^GAHWJU:JIQ3A3=2495
M)+ENN=N5G=Z/F:\W;4_SW/CK^QU^TO\ LSW;1_%+X9>-/#]OE -3FT?5+2W@
MF))@(E:V0J516DPSA0JD_P )-?0?[*?_  5<_:R_9&:QTWP#\1-9N?"UO';I
M<:4=:O$_=6T;QHK0.[C"EEW )\I0,[$*5/\ 7]^T1^VG=_M,^&[WP_\ %G]G
MTZNVHVTEM'=KX<CDN+6Z>*=(9BXCWK;H)271>&4+M*D$G^2/]JS]@CQIX*U#
M6_B%X*\)ZDWAZ2[U'4[J)[,I!IEE)*S>68FC^14CD*!?O+P2Q&TU\/GO#..R
M>E',,7FN73A4G&3PRH2JU[<VJYIQY(IJZMS+5WT3N?6Y5Q'DV:PEAL1AY?6'
M*2;M247'2">DDW=ZW5]-%?=_T-?LF?\ !8_]K#]L!M+T#P?XJF'BWR5\W0AJ
M,C7CF$JK%;= 9I&9B%0^4?,?( 8G%?H</BU_P52B8W=EHWBUYXE/DS"VU Q%
M0QP1M@PRD?-G )W*#P:_@4_9J_:'^(/[*_Q;TGXM_#>[DT?4-$OH+>>)G>%;
MCRKJ"2:+8K* 0(<DAT*L7#$@[:_NS_9H_P""Z'QB^)WPG\+:LGP]BUG4K'3[
M-+^YL]$29;BX:!1))/*H(?S#%([,K%I'!8GU^JR"K2Q5"A*G@<KQT:<(^T^M
MUZ>"E&]N10C"G-23E>\Y-)7:LK7?A<1Y#1P].>)PCA2C5;G9KWMM4FO=VLO>
M=[ZNR9Z(OQ,_X*LQQB4Z7XS$CX<_Z-J;DL[#.UOLX(')SMZ+D'C-$7Q0_P""
MJD/VJ[71?&CW?D[5!M-38LHR X0P]5Z;@N-H]J[ZX_X+$_':261!\*9539\H
M3P^HP0 ,#*D;2H&#@$@XR#Q4<?\ P6&^.JA2?A>R';M(;PZS.!DD!MJ8.X8.
M<D%2. <5]=+!.<4Z>4\/X5SCR\WU^C4=G?[?L&TM=D^9;VUU^&PU6MAZDDZW
M*HMO1QL[)7Z[Z?=;0W?@Q\2?^"GDGQ%\%VOBG1/%9T*YU&.34A<6VII'#"\G
M[QI&E@\M-Z]%8X.,* 6-?U)^$+O6+C0=%.N*Z7\EA;-?B7Y3'<^4@='^[M(9
MFR&(Y'0$&OY5!_P6/^/JN/)^%MPSQG*R1:0]NP'; *J=HXQ@C![Y)%6H_P#@
MLY^TA))+!%\/-0MF2W-P5_LVX;S"I^4$@\;@26 8C\.!^=\0\$9CBZ%:<*^2
M8:#K0D_8UG5FW)RY/>I0C*<;WYX*,N31OXC[#).(I8?%PDZS3C"HD[I6TCRV
M=]WKH^G?<_K:$<91E1@@)QN7Y^ 0/E/4EL!B><C_ &1BK:3JB)&9"_\ &IC(
MW;3G.1R>I!.<$9 / !;\"/V%_P#@I%\;OVC?'UKX3\:^"Y])M)FM(XKA;%[1
M8VFF>*5Y'( "C8,AR<MGD8&/W@LI(PJ^< L\:^40I^5U< AE)W?,-O(R<9 X
MP0?R',<KKY955.<H5Y*?+:AKS25[<JE[R3L[<R7<_6LNS+#XV@I.K>I*_6#O
M+W=&W*Z>KOU.E2?"*V2R[1\H&7'3DD'./?:.H]J=]KC]&_(G^0Q^59^]!&#@
MA=JC(." ,=3R.HP2 ,]>]5_-C[338[?Z_I_P$!?R 'H *\YU*D79X>JETNX+
MY;K;[^YVNR?NN^G>/SV=MS8O$$D)C9_+5BNYBN0 &4@'T)/ _'TK^>/_ (+I
M_P#!)JP_X*+_  F75?!EKIL'Q/\  T4TMG<R69GN[TQ6=U' B8D7(:5X5 *G
M"[DR"V1_0[=;3&58D @D8Z[E9"O.#W_.L%8H3(YB1EO74>:,G$H'4R8[$@@C
M(RHR, _-W"/\C_X=?$#_ (*O?\$JO%NJ_#GPMH_Q#_LC2-3D^P0"SUF329FC
M,D6Z)3!=*$V)C8I5&!4CH")/C/XR_P""M/\ P4QT_5;CQSH'Q$C\.6=K+J%W
M9_9-;6VFBM%:V:);46Z)M<&1@"RDKD!2<-7^K/XG^"/PE^(4SR>,_A[X6UR[
MC??')>Z18W$A8@_*SR1;\="@SUR222-O0>'OA5\-_"^FR6/ASP#X4TBTF00S
MVUCH>GQ(\9+K+&W[G.#EMQR2Q;TH _S4/^#97X$_&;X4_M_6-WXV^'GBGPYI
MT5_:Z?=7.I:-?VT3&WFN(Y=TEQ%&/D*EL[B,DDD]\7_@ZGA-S^W+IL5JT<US
M=Q_8[,,C.2US&ZQ;$7(;!E;)R/F*@-@ G_2^T+X5_#;PUJ(UOPWX'\/>']8:
MZ=I=3L=+M+>8O('+R>8L)(8,<Y"[@2S$9Z?YI_\ P<Y3//\ \%"O RQ7WF)%
MJ>G[2T2%0717=W&S!" ;4!W;4^;!." #XJ^ WQ#_ ."KW_!/GP5HGBCX0V'C
MF;P-XJLK2_B>PLM6N+..V:+>JQ110RPJ7CE# @&3Y/OE0-FSX_\ BO\ \%<O
M^"JMSIGPWUW1/B#/X?OM1_LZ\M[NQUN&$QR?,99B;:(O&AC#.-VQ@I#*5!%?
MZ.W_  3A\ ^ OB-^P7\#K7QKX1\/^(H_^$(TB%GO-,AD+R?V<BJYP SL-J9Q
MCJ>.3C[@\%?!CX8^ 56;P9\.?"OAV]21\7=EI4$=P< X<%PV'(<@X&,9Z')8
M _%#_@A#_P $B]/_ ."='P=36_%EG#>?%OQE8:<^L:BT!2XL6$$DKV8=V#H8
MY90&BV+D+AB>,_P__P#!Q;X>OO$?_!37Q%X3M%EFNM?^SPV,=NA>9K^:6X$6
MQ4P\AX(6++(&P0"<U_K,6XW@/(6,FY0^2%!*\;@B[4 *L2P*]>>,$'_*K_X+
MO-=-_P %C?#ZVTB0W2^(-"\F0Y7:!=W'REE)Y< C*\\G/N >*_!#XZ_\%>O^
M"<'AC2+#P!IOCS4/ NJZ<EQHT::-J\MM#9RP))"82UK.N$C<., KC^,C<#%K
M"_\ !5K_ (*[>*M'\&^--+\9#0KNY6/4'U&PU:WLI8?-:9Q)&UM'$H82",$!
ML%R>F5/^F7^R[\)?AI\0?V9O@K+XY\#^&O$%PO@+PP#+?VWGDYTFV8G:['=N
M('RL""O!R"V?JKPO\(?AAX'F-UX1\!>&/#EQC"SZ5HUC:/'QM!0P1*%.=H)"
MG(&#W( /R*_X(N?\$N?#G_!./]G^RTS4)X[GQ]XHLQ>:O>?9Y(YH;C8))(<W
M#,L1#(0NR.,L%WL6()'\<G_!Q?\ !#XI>,?^"H7@WQ1X9\ >+-9T74+^P@DU
M/2]#N;JR79J\($OVB&UDA54(#.,\G/*J01_ID>7.CEKA_ML; ;8HU5?)7)!"
MXP"64_,.3RQZ]?-=?^$?P\\6ZK%JOB3P'X;UF^APL%WJ^G6]Q<PA=SIMD*%U
MD#G"L.H"EAUH _/3P[X?UP?\$G])\.7=I-;:M:_!FTM&M%AD6]:Y&ENODM $
MRKD.$VA1E5P>>3_#/_P0E^!GQC\-?\%4K_7_ !#X&\5Z-H%KXFN)'UF]TB\M
M[257U!72(RRVT<0WQA@CB0GCD#!!_P!-X>'=-BTF70HM+TY='$"VZ:9LC%D(
MMH'E^0RE0N"1T89Z$ Y'&Z!\(?AGX4U5->T?P+X8TC5,,?M>G:=;QSM*0"TS
MRHH(<8X)'WB0!R< 'YC?\%>?^":?A7_@HS^S[JGAV%+.P\=Z19S3^'+N>V=K
MI)UM$@55\F1!-P#Y:R*ZAAP,@!?\^#1/#_\ P5C_ ."17C[5/"W@/1O&DGAW
M1=3N$M+JWT_4Y=/O4>4)')&D-JR980?NMA49)4J0F3_K-LCRW$=U# '9=Q&5
MW(H*# (/&XL21Q^0!QY_XP^#_P -?B+)&?'W@#P]X@$9+I)J&GI+*)<?(VX,
M&8Y.>3CDD=A0!_E;>//VB_\ @L+_ ,%*]6L?A9K6G?$C2+?4KVWBNI[>PU^R
M@>"=U$@W+#%"LF%+%BA(49#+DD_W$?\ !#+_ ()7>(?^"?\ \)+KQ/\ $W7M
M=\4_$/QQI&F75S!K&I7U[/8-):W+7$1M;V>1 8VO0<>2I7;G;FOVT\*?!/X7
M>!+Q+GPCX"\-:.[%4>>TTV!)$C!)_=LREP%'.<DKGOUKTA;63S4F+2&2-&CC
M+2$E%R551_"-JD@?*1@ $DK@@'\??_!P?_P0SUK]J.*U_:/_ &>X&;XC:3"E
MQJEG:6\SZE?W$0P9,Q-)*RERH(5%&?XT( /\L_PG_;H_X+!?L'?VE\)-.T+X
MBR1:-;_V3:07FCZY>1QV\#O:!;=[BVNECPNU 8EC*JHV\ BO]9FZADG.9$4A
MHQ',CQI)'.%VD;E.X;R5&!M ZG/:O(M6^ ?P7\0:H=7\3_#+PSJE_(YDDO;W
M2[:620')#J-HW9R&&X<,6/K0!_EM>#_V4?\ @IQ_P5W^,6E7WQBT_P ;V'A[
M4KBUMKN35[+4X])2.-FG::..2.WV"-",EBC 1$JS#@?Z0?\ P3F_8:\+?L&_
MLV^"_@[I5E:76J6VC6D/B">R@:,->%8Y':9C+*SNI+"1F?#,I7))K[:\/?#G
MP5X.LU'@WPQH.C+)ND#6-C!:/G' 'EJKX &"<L,$9SDUU,:3D*IG<$G=(8]A
M\YB#\LC/D-ACG<,#;@9.2:<92A*,HWYHM2C9J+NG?1MI+U;5M=;V&K-3A))Q
MJ1<97[--?Y;_ )'\Y'_!4C_@F=K/Q,U>^^,/PN CU_3"+P)8V+&ZD?[4;D["
MC*$8H\J\+\YQN!()/Y*>#OVM_P!OGX!6:^"[?0/&5QIVE$6*1W-M=SK-)$=J
M2Q^9;M)L+'<%#[0. *_NFN8#<QR6S6\,MO-$RRQ2A7#Y8K@JPP&P=QZC/3IS
MY1JWP1^&FKWCW.I^"?#]S=.K&-Y+&,[I"=Q+%L@,>,$ #(P.,9_1LJX^KT,)
M+!YCAHUZ4(QY.>%*M+W8J,;<_-RO:3Y+6:MLV?FV<<#_ %IUZN5U)87$5)*2
MJ<_(HOGCSM)-7O!SC=W=I7UL?QH_#S]FG]KC]N+XCZ3X@^)D7B"VTG4-0\][
M751>&)8 T<S*B,D<:CJJJ%7 )'.:_KB^ ?P4TGX"_"&R\!Z=I]L+W3-'*7;6
M\93SF2-P%+'+[R),'.?N/@#D'WC1O">F^';1+/1='TG3##)"(_LEM%#B-%^9
M2=@!RG&1CH"<#@]%,H5$0Q%[ABK.<*5ER"&29N?EVD !1SN;OG'!Q'QMF6=X
M'#Y=&5.CA</B</6]G%*/-[*I3LY6M%?NXM/E^=CTLGX4CD^'G*>+YZTZ<_K$
MG!R4E*+3M))MOE;LG?6RV=C^*SXI?#OQ_>?\%$]'U9?!.L262>,8V:^33KEH
M<#56^\^SRRJ@YR6'RMDY'3^QCPY'=+\/M#-POE>7X>19K?&"9$B,6/F 8#L1
MQ\V23WH7X8>#9-7&M/X5T>35!=_:3?O:1B<.1R_F$,YQEF7!&'.XDY ';3P3
M_-]FBBDC,/D")_EC2($;1Y? /0=<8;GGMPYUQ=6SB. P\Y^T67_NZ2FY-12T
MM&[VC9\KC=V5[LYLFR"&7U,7B:*;6(FZE-RCRRJ7<G:<>522=VG9+2S5]6?Q
M5_M(_"[QYJ/_  4<T;6[3PSK$^B2^-[.4W-OI]P]OLCU<NKEUR-JHH?)8 #G
M')Q_51\3?@1I7QV^ ?\ PK[6HBDEUH<0MFN8F+)<?8FC5L*RR(I)V(<\,P]*
M]VF^&'A*YU6/6YO"FASZNDD,\=[):QM.DT2HP96(.WY\E@N QZ\CCT9;:0@E
MU$#!1B.(*(EVC:%0!3E0N#@-C(R?=YKQ;F.+HY5"FW*OEN(I3<_:)0C3ARN#
MI7DFYJR35[)IZ)ZBR_A+ 4L%B(XBFG6G[3D=H<K<JM1WD[;I26SW5GY?PM?$
MS]E[]JW]@SXFW6N?#:77+OP_=ZC^[BTNVO"OD)<SRQQDJLBA%5E+N#\YYX)&
M-"Z_::_X* ?'"UF^&RZ3XN2PU&%@;HV]T4@"D/(&WVH<,#%G <YQU)(-?VP:
MSX.\/^*H?+\0Z#INL6B,\86_M89'# ;7==R KP 03D G&>F<;1/A)\//#\[2
M>'_"6C:?=R @W T^WP 6.,N$.TDL>.Z\=17VJ\1J5:IA<3B\LHUZV'4&I2C2
ME.52*BN=U*EY7O%/:Z6BV1\Q5X"S#WOJV.G3I5N>]*+E:*;:2:A==')=&WKJ
M?PA?#GX!_&+PE\?_  =;>,?"VMW6J2:S875WJSV%Z%4OJ-M(6DD(V[!\[D]O
MFSDY%?LO_P %MOB9^UC\*_V8?A]XN_9DT_7YO$'A:QT:XOX-&2^\V<-<PQS%
MXK<;@Z)NW#D[2& .:_HPN_ACX&N;Z/4=2\,:3-J=MY1CO5L;4NS1R95FD,1(
M^8 %5( XV@GD[^J>&=$UVPEL=?T32M7TK:4-GJ%G#-$\;?=B$;HRE "&^Z.,
M<Y )\+CKC_%<5U,$XX6%&.&A&$XM1<4EHK):-\J5K*UV[V/HN$>#)9#.5:K5
ME-N?.IN=W)W;UB]4FW9NUTDFNY_F@V?_  <'?\%08/ E]\,/$/P@\3ZMJ-YH
M$VER3:CHEW--FYB-LX0W%DT@E8<JX!=<9QVKWO\ X($?\$Q_VA?BU^V)'^V3
M\=_#>H^%[2'6Y]8>UU'1[JSAFDDB%T&1YHK=2"TI4D+APN N017]Z<_[('[,
M%UJLNNW/P>\&/>2RK+O.A61,;*5;Y%2$A58C!5R201@*"2??/#/A[P]X>L8=
M&\/:1I^CZ+;(52STZT@LX0$1?+WK#&A)4 8P1(.I8@@5^>2J.I4<K:2UOR\O
M1=%HM4[?YGZ'!M>T4E;FG>%KV<5J^;HG=Z6MML?A]_P6H_X),^&_^"CGP9FD
M\.V%OI'Q&\+6R+HNH26BM>7S0P[8D1?E1VP%Y;S&#<CD8/\ !)IO@_\ X*U?
M\$L_%VH^ O VD^/[C0[2XO%@-AI&MRVOE+</ "CI"X4,%5UQM3#%4ZBO];J-
M9))BI!PJHL1!.,9 . 6/7U() QTX!XOQ%\._!?BJYGO/$?A;0M?N701LVI:;
M:W+83D;C+"Q )&XCD;L';C. :C9M]S^/C_@W]_;X_;S_ &COBYXL\&_M-Z/X
MGLM"70+A].NM<MM2L[2X GTJ/RPD]O'-N8RSE1)(I."0I!K\"_V]O@I\9M4_
MX+3:;XGT[X:Z_=:1:_%#1Y6O;71KUM.:R36D_P!),HM&C8>7&2[-*=K+G)!Q
M7^G=X:^$WP_\*";4O#'@[P[X;U.5 C7FEZ79V]PR"1'))2'!R57=A.BCJ>:9
MJ'P8^%FJ:LGB75/AYX8U/Q&3'(^MSZ7:MJ(E0 !EDV@AE<9SCJ6<<G !GS+X
MZ_9W\.?M0?L;:-\(?'-K:VT>O^ K+3%CN8G"VLG]GM 08PZ-!(!*5W JQY(V
MU_G'?M3?\$W/^"@G_!(K]H3Q'\1?V<$\7:KX7@UF34[6[\.6&I36TEI!<SW,
M%MB 3;PD,:G=([L& 9@U?ZHR6-G:B'%J(;>%&CBMQLCBX "@1IM!4 '("@_Q
M$DXK&\2>$?"GC:V.E>,/#^EZ_;2[GCMM2LXIE*!6C"NS+O?*D  R\!L'@X(!
M_E4^)_\ @J;_ ,%E?VB] A^#$&@^/K:UO;5;22.WT?6+2_D;;E3]J%HA(C;#
M2;R_R!PN#@U^_P#_ ,$%_P#@BW\=?!OBNT_:G_:G\3^*+;7+FXLM=L]"UB]U
MD2[II([^XA>!KR-7<M*H"/"1CG:1D#^PS3?V:?@-H5W%>V/PI\%V%_%+))#>
M1:1$'$FYG4[OF9L$*,,"0>!D X]?M;(V,"V\*VB6\1+6=M;VPBCA9!M180JA
M548 V[L$;1C(.0#^+'_@[E^'/CSQ_P#"OX9:=X'\':UXDATEK-MVB:5=7UUL
M0R[1(EO%(P(4J'!^\#NZ\#]%/^#8[P?XK\#_ /!/RTT'Q7HFI>&=36ZTJ5K'
M5+62QO=HAE)7[-,JR;AN4,3R2< =0?Z%_%?@'P;XTMXU\;>&=%\0)@!(=7TZ
M"]1"LF0R1R(ZAEQP=Q 4],=+V@^#/"/@RR33_"NA6&A641A81Z=;I;QY504(
MCC 1<-CY54<\D=: /Y#?^#O7P%XT^(_[-_PNMO OA/Q!XJN]-U5)[U-(TVZO
M)8T?5 A=XH(9" D;%F)()R"" ":^I/\ @UT^'^L^#_\ @GVWA[QSX>U31KFY
MN[I);'6=-F@G^RW<]Q#/&\%Q#']^,C!*AE#$Y).*_H\\7> ?!_CRW^R^-?#>
MD>)].9#'%9:G9Q7$<8W,_F!6&5)9LAB<YVJ<XJ]X7\(^'/ NG0:7X/T71?#&
MDI&%6QT^S6",C;QYB(O)W#)(9<,2<'=0!_")_P %RO\ @@9\4KKXG:A^T[^R
MI#>QZE<7::W/IOAZRNA.+[[?<B>9;BUD\Z)FMFMSE',:JG,; C'XI^ _V_O^
M"SG[+T*_#RR\/_$>2/1UETZ&.XT[691(ENJPF1YOL\C2%5<;6:0X(PO!)'^L
M.;59XI$F>WN;)E:)K62&&:-@[EV<QR1LIW!F ++DKM')'/FVH?!+X2ZS/+=7
M_P +O!5Z]PBM-/=:#ITDSXP?,,I@R RG#8..0-HP, 'X]?L@>%/%/_!13_@F
M=<>"_P!IK2XV\<^*-'OK:4:O;3)<:?=3VL?EN'(MY0R3[@ =IP'RQY!_AO\
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MLT_O_/D?\%1/V&R2Q^#&F9("D-I-F!QQT,0Z$8^H]SF0?\%1/V'<#'P1TM@
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M !T )XJS10!22PA4'(SNY*]@2.0HY 7.3@#DX)/ J,601LJ!P6"[CN 3=E0
M> 0 HR,'BM&B@"D(F5ANV\Y(PJ]<CJ ,$#/0\ XXXX9+'#N1Y-NX9*Y48SQD
MX ]AWX[<<5;D!RI )^\#C'&<8ZD>E1%9,Y5#T .X@#C.,<]>3G\* *30V\H<
MDKN(4\J-BL !A0.>0,<X)"C)]'K#MCD#A6&U2IVC=RS<ENHXY ']W Z"K8$N
M?F3C_9(/YC/3W_\ KTUDD;(4%0RX.0.<9([\8YQ[G!'-)IR3BFDVK7>R]?E^
M),U>$U:]XRT[^Z]"H%*#&T$$=P#G&<=.O4]>G0=\*%8D!51#D<F,'O[\_EZ]
ML"K*QR*<D%LKV &#G///)Y].,8I6CD?A<KP1D@<Y_P"!9XQG&,>_:O+>$J1Q
M+E&<[7O=6Y-8:ZKSZ7W"G&*A"/)'2$5JI7^%732=K]-O7L452-=K D%02,Y)
M&<YSV.!P,?\ UJL>4S$Y<C Y&,97G.?0>I']!5_8OI^I_P :@1"K2@JQ4@*A
MZY&W#=^YQR?PXKIC0JMZS:6NKY7^-Q*G%*R6FKM9-:MOJN[OZV,J0K'NC6,,
M 3T R-I*C_@1XR2!G!Y.33\(VX*BJ",9'7J>^!C(X(YSZ\5=6!QN.,EF))X&
M2?0$CC.:=LD7^ '/J0?Y9K7V,DK*K+F772V]W_7W&ZE34%%4USKJT[;WZ6Z=
MF5HD4),K#(9 J%AN+/\ .<9P3G.T_EZ#$;6N P*%E;:"BXVL0W P< <E>I(*
MC;CI5]5<9)0C..%QCC//;GG]*1DF."@ PZGY^N%*GC&1C.3ZGD9QC&L4XQ2;
MYFM&^^^OXD-W;=DO);$0MHV0)]G"*?O#:AY+$$Y]E]N?>I8[.*+B,*H)RP"+
MSG (S[@ 'CIQ4\?F8/F8SVV],?SS_P#6]ZDJA$2P1JV\#GMTP.,< #'_ -<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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@ '6'\R*DHH K?/\ W#^?_P!:CY_[A_/_ .M5FB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
